#BEGIN_DRUGCARD DB00129

# AHFS_Codes:
Not Available

# ATC_Codes:
A05BA06
D11AX16
P01CX03

# Absorption:
Absorbed from the small intestine via a sodium-dependent active transport process

# Biotransformation:
Ornithine undergoes extensive metabolism in the liver to L-arginine, polyamines, and proline, and several other metabolites.

# Brand_Mixtures:
Not Available

# Brand_Names:
OKG

# CAS_Registry_Number:
70-26-8

# ChEBI_ID:
15729

# Chemical_Formula:
C5H12N2O2

# Chemical_IUPAC_Name:
(2S)-2,5-diaminopentanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Ornithine is an amino acid produced in the urea cycle by the splitting off of urea from arginine. It is a central part of the urea cycle, which allows for the disposal of excess nitrogen. L-Ornithine is a precursor of citrulline and arginine.

# Dosage_Forms:
Capsule	Oral
Capsule	Oral
Capsule	Oral
Capsule	Oral
Powder	Oral

# Drug_Category:
Dietary supplement
Micronutrient
Non-Essential Amino Acids

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Nutraceutical
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-4.22

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Appreciable

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
L-Ornithine

# HET_ID:
ORN

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C5H12N2O2/c6-3-1-2-4(7)5(8)9/h4H,1-3,6-7H2,(H,8,9)/t4-/m0/s1

# InChI_Key:
InChIKey=AHLPHDHHMVZTML-BYPYZUCNSA-N

# Indication:
Used for nutritional supplementation, also for treating dietary shortage or imbalance. It has been claimed that ornithine improves athletic performance, has anabolic effects, has wound-healing effects, and is immuno-enhancing.

# KEGG_Compound_ID:
C01602

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
129

# Mechanism_Of_Action:
L-Ornithine is metabolised to L-arginine. L-arginine stimulates the pituitary release of growth hormone. Burns or other injuries affect the state of L-arginine in tissues throughout the body. As De novo synthesis of L-arginine during these conditions is usually not sufficient for normal immune function, nor for normal protein synthesis, L-ornithine may have immunomodulatory and wound-healing activities under these conditions (by virtue of its metabolism to L-arginine).

# Melting_Point:
140 °C

# Molecular_Weight_Avg:
132.161

# Molecular_Weight_Mono:
132.089877638

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
4CEV

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/lor_0190.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA164783814

# Pharmacology:
A non-essential and nonprotein amino acid, ornithine is critical for the production of the body's proteins, enzymes and muscle tissue. Ornithine plays a central role in the urea cycle and is important for the disposal of excess nitrogen (ammonia). Ornithine is the starting point for the synthesis of many polyamines such as putrescine and spermine. Ornithine supplements are claimed to enhance the release of growth hormone and to burn excess body fat. Ornithine is necessary for proper immune function and good liver function.

# Predicted_LogP_Hydrophobicity:
-3.6

# Predicted_LogS:
0.11

# Predicted_Water_Solubility:
1.72e+02 g/l

# Primary_Accession_No:
DB00129

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
6262

# PubChem_Substance_ID:
46505239

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
NUTR00043

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NCCC[C@H](N)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
(S)-2,5-Diaminopentanoate
(S)-2,5-Diaminopentanoic acid
(S)-2,5-diaminovaleric acid
(S)-ornithine

# Synthesis_Reference:
Not Available

# Toxicity:
Oral, rat LD<sub>50</sub> = 10000 mg/kg

# Update_Date:
2013-02-08 16:19:07 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Ornithine

# pKa_Isoelectric_Point:
1.94 (at 25 °C)

# Drug_Target_10_Cellular_Location:
Mitochondrion
mitochondrial inner membrane
multi-pass membrane protein

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
14759633	Korman SH, Kanazawa N, Abu-Libdeh B, Gutman A, Tsujino S: Hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome with evidence of mitochondrial dysfunction due to a novel SLC25A15 (ORNT1) gene mutation in a Palestinian family. J Neurol Sci. 2004 Mar 15;218(1-2):53-8.
16940241	Camacho JA, Mardach R, Rioseco-Camacho N, Ruiz-Pesini E, Derbeneva O, Andrade D, Zaldivar F, Qu Y, Cederbaum SD: Clinical and functional characterization of a human ORNT1 mutation (T32R) in the hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome. Pediatr Res. 2006 Oct;60(4):423-9. Epub 2006 Aug 28.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
SLC25A15

# Drug_Target_10_GenBank_ID_Gene:
AF112968

# Drug_Target_10_GenBank_ID_Protein:
5565862

# Drug_Target_10_GeneCard_ID:
SLC25A15

# Drug_Target_10_Gene_Name:
SLC25A15

# Drug_Target_10_Gene_Sequence:
>906 bp
ATGAAATCCAATCCTGCTATCCAGGCTGCCATTGACCTCACAGCGGGGGCTGCAGGAGGT
ACAGCATGTGTACTGACCGGGCAGCCCTTTGACACAATGAAAGTGAAGATGCAGACGTTC
CCTGACCTGTACCGGGGCCTCACCGACTGCTGCCTGAAGACTTACTCCCAGGTGGGCTTC
CGTGGCTTCTACAAGGGTACCAGTCCAGCACTAATCGCCAACATCGCTGAGAACTCAGTC
CTCTTCATGTGCTACGGCTTCTGCCAGCAGGTGGTGCGGAAAGTGGCTGGATTGGACAAG
CAGGCAAAGCTGAGTGATCTGCAGAATGCAGCCGCCGGTTCCTTCGCCTCTGCCTTTGCT
GCACTGGTGCTCTGCCCCACGGAGCTCGTGAAGTGCCGGCTGCAGACCATGTATGAGATG
GAGACATCAGGGAAGATAGCCAAGAGCCAGAATACAGTGTGGTCTGTCATCAAAAGTATT
CTTAGGAAAGATGGCCCCTTGGGGTTCTACCATGGACTCTCAAGCACTTTACTTCGAGAA
GTACCAGGCTATTTCTTCTTCTTCGGTGGCTATGAACTGAGCCGGTCCTTTTTTGCATCA
GGGAGATCAAAAGATGAATTAGGCCCTGTACCTTTGATGTTAAGTGGTGGAGTTGGTGGG
ATTTGCCTCTGGCTTGCGGTATACCCAGTGGATTGTATCAAATCCAGAATTCAAGTTCTT
TCCATGTCTGGAAAACAGGCAGGATTTATCAGAACCTTTATAAATGTTGTGAAAAATGAA
GGAATAACGGCCTTATATTCTGGACTGAAACCTACTATGATTCGAGCATTCCCTGCCAAT
GGAGCACTCTTTTTGGCCTACGAATATAGCAGGAAGTTGATGATGAACCAGTTGGAAGCA
TACTGA

# Drug_Target_10_General_Function:
Amino acid transport and metabolism

# Drug_Target_10_General_References:
10369256	Camacho JA, Obie C, Biery B, Goodman BK, Hu CA, Almashanu S, Steel G, Casey R, Lambert M, Mitchell GA, Valle D: Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter. Nat Genet. 1999 Jun;22(2):151-8.
10805333	Tsujino S, Kanazawa N, Ohashi T, Eto Y, Saito T, Kira J, Yamada T: Three novel mutations (G27E, insAAC, R179X) in the ORNT1 gene of Japanese patients with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome. Ann Neurol. 2000 May;47(5):625-31.
11552031	Salvi S, Santorelli FM, Bertini E, Boldrini R, Meli C, Donati A, Burlina AB, Rizzo C, Di Capua M, Fariello G, Dionisi-Vici C: Clinical and molecular findings in hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. Neurology. 2001 Sep 11;57(5):911-4.
11668643	Salvi S, Dionisi-Vici C, Bertini E, Verardo M, Santorelli FM: Seven novel mutations in the ORNT1 gene (SLC25A15) in patients with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome. Hum Mutat. 2001 Nov;18(5):460.
11814739	Miyamoto T, Kanazawa N, Hayakawa C, Tsujino S: A novel mutation, P126R, in a Japanese patient with HHH syndrome. Pediatr Neurol. 2002 Jan;26(1):65-7.

# Drug_Target_10_HGNC_ID:
HGNC:10985

# Drug_Target_10_HPRD_ID:
04838

# Drug_Target_10_ID:
224

# Drug_Target_10_Locus:
13q14

# Drug_Target_10_Molecular_Weight:
32737

# Drug_Target_10_Name:
Mitochondrial ornithine transporter 1

# Drug_Target_10_Number_of_Residues:
301

# Drug_Target_10_PDB_ID:
Not Available

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00153	Mito_carr

# Drug_Target_10_Protein_Sequence:
>Mitochondrial ornithine transporter 1
MKSNPAIQAAIDLTAGAAGGTACVLTGQPFDTMKVKMQTFPDLYRGLTDCCLKTYSQVGF
RGFYKGTSPALIANIAENSVLFMCYGFCQQVVRKVAGLDKQAKLSDLQNAAAGSFASAFA
ALVLCPTELVKCRLQTMYEMETSGKIAKSQNTVWSVIKSILRKDGPLGFYHGLSSTLLRE
VPGYFFFFGGYELSRSFFASGRSKDELGPVPLMLSGGVGGICLWLAVYPVDCIKSRIQVL
SMSGKQAGFIRTFINVVKNEGITALYSGLKPTMIRAFPANGALFLAYEYSRKLMMNQLEA
Y

# Drug_Target_10_Reaction:
Not Available

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
Ornithine transport across inner mitochondrial membrane, from the cytoplasm to the matrix

# Drug_Target_10_SwissProt_ID:
Q9Y619

# Drug_Target_10_SwissProt_Name:
ORNT1_HUMAN

# Drug_Target_10_Synonyms:
Solute carrier family 25 member 15

# Drug_Target_10_Theoretical_pI:
9.43

# Drug_Target_10_Transmembrane_Regions:
5-25
68-88
110-130
168-188
207-227
237-257

# Drug_Target_11_Cellular_Location:
Cell membrane
multi-pass membrane protein

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9079705	Hosokawa H, Sawamura T, Kobayashi S, Ninomiya H, Miwa S, Masaki T: Cloning and characterization of a brain-specific cationic amino acid transporter. J Biol Chem. 1997 Mar 28;272(13):8717-22.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
SLC7A3

# Drug_Target_11_GenBank_ID_Gene:
AF320612

# Drug_Target_11_GenBank_ID_Protein:
17224957

# Drug_Target_11_GeneCard_ID:
SLC7A3

# Drug_Target_11_Gene_Name:
SLC7A3

# Drug_Target_11_Gene_Sequence:
>1860 bp
ATGCCGTGGCAAGCATTTCGCAGATTTGGTCAAAAGCTGGTACGCAGACGTACACTGGAG
TCAGGCATGGCTGAGACTCGCCTTGCCAGATGCCTAAGCACCCTGGATTTAGTGGCCCTG
GGTGTGGGCAGCACATTGGGTGCAGGCGTGTATGTCCTAGCTGGCGAGGTGGCCAAAGAT
AAAGCAGGGCCATCCATTGTGATCTGCTTTTTGGTGGCTGCCCTGTCTTCTGTGTTGGCT
GGGCTGTGCTATGCGGAGTTTGGTGCCCGGGTTCCCCGTTCTGGTTCGGCATATCTCTAC
AGCTATGTCACTGTGGGTGAACTCTGGGCCTTCACCACTGGCTGGAACCTCATCCTCTCC
TATGTCATTGGTACAGCCAGTGTGGCCCGGGCCTGGAGCTCTGCTTTTGACAACCTGATT
GGGAACCACATCTCTAAGACTCTGCAGGGGTCCATTGCACTGCACGTGCCCCATGTCCTT
GCAGAATATCCAGATTTCTTTGCTTTGGGCCTCGTGTTGCTGCTCACTGGATTGTTGGCT
CTCGGGGCTAGTGAGTCGGCCCTGGTTACCAAAGTGTTCACAGGCGTGAACCTTTTGGTT
CTTGGGTTCGTCATGATCTCTGGCTTCGTTAAGGGGGACGTGCACAACTGGAAGCTCACA
GAAGAGGACTACGAATTGGCCATGGCTGAACTCAATGACACCTATAGCTTGGGTCCTCTG
GGCTCTGGAGGATTTGTGCCTTTCGGCTTCGAGGGAATTCTCCGTGGAGCAGCGACCTGT
TTCTATGCATTTGTTGGTTTCGACTGTATTGCTACCACTGGAGAAGAAGCCCAGAATCCC
CAGCGTTCCATCCCGATGGGCATTGTGATCTCACTGTCTGTCTGCTTTTTGGCGTATTTT
GCTGTCTCTTCTGCACTCACCCTGATGATGCCTTACTACCAGCTTCAGCCTGAGAGCCCT
TTGCCTGAGGCATTTCTCTACATTGGATGGGCTCCTGCCCGCTATGTTGTGGCTGTTGGC
TCCCTCTGTGCTCTTTCTACCAGCCTCCTGGGCTCCATGTTCCCCATGCCTCGGGTGATC
TACGCGATGGCAGAGGATGGCCTCCTGTTCCGTGTACTTGCTCGGATCCACACCGGCACA
CGCACCCCAATCATAGCCACCGTGGTCTCTGGCATTATTGCAGCATTCATGGCATTCCTC
TTCAAACTCACTGATCTTGTGGACCTCATGTCAATTGGGACCCTGCTTGCTTACTCCCTG
GTGTCGATTTGTGTTCTCATCCTCAGGTATCAACCTGATCAGGAGACAAAGACTGGGGAA
GAAGTGGAGTTGCAGGAGGAGGCAATAACTACTGAATCAGAGAAGTTGACCCTATGGGGA
CTATTTTTCCCACTCAACTCCATCCCCACTCCACTCTCTGGCCAAATTGTCTATGTTTGT
TCCTCATTGCTTGCTGTCCTGCTGACTGCTCTTTGCCTGGTGCTGGCCCAGTGGTCAGTT
CCATTGCTTTCTGGAGACCTGCTGTGGACTGCAGTGGTTGTGCTGCTCCTGCTGCTCATT
ATTGGGATCATTGTGGTCATCTGGAGACAGCCACAGAGTTCCACTCCCCTTCACTTTAAG
GTGCCTGCTTTGCCTCTCCTCCCACTAATGAGCATCTTTGTGAATATTTACCTTATGATG
CAGATGACAGCTGGTACCTGGGCCCGATTTGGGGTCTGGATGCTGATTGGCTTTGCTATC
TACTTCGGCTATGGGATCCAGCACAGCCTGGAAGAGATTAAGAGTAACCAACCCTCACGC
AAGTCTAGAGCCAAAACTGTAGACCTTGATCCCGGCACTCTCTATGTCCACTCAGTTTGA

# Drug_Target_11_General_Function:
Amino acid transport and metabolism

# Drug_Target_11_General_References:
11591158	Vekony N, Wolf S, Boissel JP, Gnauert K, Closs EI: Human cationic amino acid transporter hCAT-3 is preferentially expressed in peripheral tissues. Biochemistry. 2001 Oct 16;40(41):12387-94.

# Drug_Target_11_HGNC_ID:
HGNC:11061

# Drug_Target_11_HPRD_ID:
02343

# Drug_Target_11_ID:
150

# Drug_Target_11_Locus:
Xq13.1

# Drug_Target_11_Molecular_Weight:
67170

# Drug_Target_11_Name:
Cationic amino acid transporter 3

# Drug_Target_11_Number_of_Residues:
619

# Drug_Target_11_PDB_ID:
Not Available

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF00324	AA_permease

# Drug_Target_11_Protein_Sequence:
>Cationic amino acid transporter 3
MPWQAFRRFGQKLVRRRTLESGMAETRLARCLSTLDLVALGVGSTLGAGVYVLAGEVAKD
KAGPSIVICFLVAALSSVLAGLCYAEFGARVPRSGSAYLYSYVTVGELWAFTTGWNLILS
YVIGTASVARAWSSAFDNLIGNHISKTLQGSIALHVPHVLAEYPDFFALGLVLLLTGLLA
LGASESALVTKVFTGVNLLVLGFVMISGFVKGDVHNWKLTEEDYELAMAELNDTYSLGPL
GSGGFVPFGFEGILRGAATCFYAFVGFDCIATTGEEAQNPQRSIPMGIVISLSVCFLAYF
AVSSALTLMMPYYQLQPESPLPEAFLYIGWAPARYVVAVGSLCALSTSLLGSMFPMPRVI
YAMAEDGLLFRVLARIHTGTRTPIIATVVSGIIAAFMAFLFKLTDLVDLMSIGTLLAYSL
VSICVLILRYQPDQETKTGEEVELQEEAITTESEKLTLWGLFFPLNSIPTPLSGQIVYVC
SSLLAVLLTALCLVLAQWSVPLLSGDLLWTAVVVLLLLLIIGIIVVIWRQPQSSTPLHFK
VPALPLLPLMSIFVNIYLMMQMTAGTWARFGVWMLIGFAIYFGYGIQHSLEEIKSNQPSR
KSRAKTVDLDPGTLYVHSV

# Drug_Target_11_Reaction:
Not Available

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
Mediates the uptake of the cationic amino acids arginine, lysine and ornithine in a sodium-independent manner

# Drug_Target_11_SwissProt_ID:
Q8WY07

# Drug_Target_11_SwissProt_Name:
CTR3_HUMAN

# Drug_Target_11_Synonyms:
CAT-3
Cationic amino acid transporter y+
Solute carrier family 7 member 3

# Drug_Target_11_Theoretical_pI:
6.11

# Drug_Target_11_Transmembrane_Regions:
37-57
62-82
108-128
163-183
192-212
234-254
286-306
336-356
383-403
407-427
476-496
507-527
541-561
570-590

# Drug_Target_12_Cellular_Location:
Not Available

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
OAZ2

# Drug_Target_12_GenBank_ID_Gene:
AF057297

# Drug_Target_12_GenBank_ID_Protein:
3766170

# Drug_Target_12_GeneCard_ID:
OAZ2

# Drug_Target_12_Gene_Name:
OAZ2

# Drug_Target_12_Gene_Sequence:
>570 bp
ATGATAAACACCCAGGACAGTAGTATTTTGCCTTTGAGTAACTGTCCCCAGCTCCAGTGC
TGCAGGCACATTGTTCCAGGGCCTCTGTGGTGCTCCGATGCCCCTCACCCACTGTCGAAG
ATCCCCGGTGGGCGAGGGGGCGGCAGGGATCCTTCTCTCTCAGCTCTAATATATAAGGAC
GAGAAGCTCACTGTGACCCAGGACCTCCCTGTGAATGATGGAAAACCTCACATCGTCCAC
TTCCAGTATGAGGTCACCGAGGTGAAGGTCTCTTCTTGGGATGCAGTCCTGTCCAGCCAG
AGCCTGTTTGTAGAAATCCCAGATGGATTATTAGCTGATGGGAGCAAAGAAGGATTGTTA
GCACTGCTAGAGTTTGCTGAAGAGAAGATGAAAGTGAACTATGTCTTCATCTGCTTCAGG
AAGGGCCGAGAAGACAGAGCTCCACTCCTGAAGACCTTCAGCTTCTTGGGCTTTGAGATT
GTACGTCCAGGCCATCCCTGTGTCCCCTCTCGGCCAGATGTGATGTTCATGGTTTATCCC
CTGGACCAGAACTTGTCCGATGAGGACTAA

# Drug_Target_12_General_Function:
Not Available

# Drug_Target_12_General_References:
10352227	Zhou J, Atkins JF, Gesteland RF: Structure of human ornithine decarboxylase antizyme 2 gene. Gene. 1999 May 31;232(2):165-71.
9782076	Ivanov IP, Gesteland RF, Atkins JF: A second mammalian antizyme: conservation of programmed ribosomal frameshifting. Genomics. 1998 Sep 1;52(2):119-29.

# Drug_Target_12_HGNC_ID:
HGNC:8096

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
3980

# Drug_Target_12_Locus:
15q22.31

# Drug_Target_12_Molecular_Weight:
21011

# Drug_Target_12_Name:
Ornithine decarboxylase antizyme 2

# Drug_Target_12_Number_of_Residues:
189

# Drug_Target_12_PDB_ID:
Not Available

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF02100	ODC_AZ

# Drug_Target_12_Protein_Sequence:
>Ornithine decarboxylase antizyme 2
MINTQDSSILPLSNCPQLQCCRHIVPGPLWCSDAPHPLSKIPGGRGGGRDPSLSALIYKD
EKLTVTQDLPVNDGKPHIVHFQYEVTEVKVSSWDAVLSSQSLFVEIPDGLLADGSKEGLL
ALLEFAEEKMKVNYVFICFRKGREDRAPLLKTFSFLGFEIVRPGHPCVPSRPDVMFMVYP
LDQNLSDED

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
Binds to, and destabilizes, ornithine decarboxylase. Does not accelerate ornithine decarboxylase degeneration

# Drug_Target_12_SwissProt_ID:
O95190

# Drug_Target_12_SwissProt_Name:
OAZ2_HUMAN

# Drug_Target_12_Synonyms:
AZ2
ODC-Az 2

# Drug_Target_12_Theoretical_pI:
5.03

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Mitochondrion. Cytoplasm. The mitochondrial form is found in the intermembrane space probably attach

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
11691635	Natesan S, Reddy SR: Compensatory changes in enzymes of arginine metabolism during renal hypertrophy in mice. Comp Biochem Physiol B Biochem Mol Biol. 2001 Dec;130(4):585-95.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5335895	Mitruka BM, Costilow RN: Arginine and ornithine catabolism by Clostridium botulinum. J Bacteriol. 1967 Jan;93(1):295-301.
7173402	Thomasset N, Quash GA, Dore JF: The differential contribution of arginase and transamidinase to ornithine biosynthesis in two achromic human melanoma cell lines. FEBS Lett. 1982 Nov 1;148(1):63-6.

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
GATM

# Drug_Target_13_GenBank_ID_Gene:
S68805

# Drug_Target_13_GenBank_ID_Protein:
545385

# Drug_Target_13_GeneCard_ID:
GATM

# Drug_Target_13_Gene_Name:
GATM

# Drug_Target_13_Gene_Sequence:
>1272 bp
ATGCTGCGGGTGCGGTGTCTGCGCGGCGGGAGCCGCGGCGCCGAGGCGGTGCACTACATC
GGATCTCGGCTTGGACGAACCTTGACAGGATGGGTGCAGCGAACTTTCCAGAGCACCCAG
GCAGCTACGGCTTCCTCCCGGAACTCCTGTGCAGCTGACGACAAAGCCACTGAGCCTCTG
CCCAAGGACTGCCCTGTCTCTTCTTACAACGAATGGGACCCCTTAGAGGAAGTGATAGTG
GGCAGAGCAGAAAACGCCTGTGTTCCACCGTTCACCATCGAGGTGAAGGCCAACACATAT
GAAAAGTACTGGCCATTTTACCAGAAGCAAGGAGGGCATTATTTTCCCAAAGATCATTTG
AAAAAGGCTGTTGCTGAAATTGAAGAAATGTGCAATATTTTAAAAACGGAAGGAGTGACA
GTAAGGAGGCCTGACCCCATTGACTGGTCATTGAAGTATAAAACTCCTGATTTTGAGTCT
ACGGGTTTATACAGTGCAATGCCTCGAGACATCCTGATAGTTGTGGGCAATGAGATTATC
GAGGCTCCCATGGCATGGCGTTCACGCTTCTTTGAGTACCGAGCGTACAGGTCAATTATC
AAAGACTACTTCCACCGTGGCGCCAAGTGGACAACAGCTCCTAAGCCCACAATGGCTGAT
GAGCTTTATAACCAGGATTATCCCATCCACTCTGTAGAAGACAGACACAAATTGGCTGCT
CAGGGAAAATTTGTGACAACTGAGTTTGAGCCATGCTTTGATGCTGCTGACTTCATTCGA
GCTGGAAGAGATATTTTTGCACAGAGAAGCCAGGTTACAAACTACCTAGGCATTGAATGG
ATGCGTAGGCATCTTGCTCCAGACTACAGAGTGCATATCATCTCCTTTAAAGATCCCAAT
CCCATGCATATTGATGCTACCTTCAACATCATTGGACCTGGTATTGTGCTTTCCAACCCT
GACCGACCATGTCACCAGATTGATCTTTTCAAGAAAGCAGGATGGACTATCATTACTCCT
CCAACACCAATCATCCCAGACGATCATCCACTCTGGATGTCATCCAAATGGCTTTCCATG
AATGTCTTAATGCTAGATGAAAAACGTGTTATGGTGGATGCCAATGAAGTTCCAATTCAA
AAGATGTTTGAAAAGCTGGGTATCACTACCATTAAAGTTAACATTCGTAATGCCAATTCC
CTGGGAGGAGGCTTCCATTGCTGGACCTGCGATGTCCGGCGCCGAGGCACCCTACAGTCC
TACTTGGACTGA

# Drug_Target_13_General_Function:
Amino acid transport and metabolism

# Drug_Target_13_General_References:
8313955	Humm A, Huber R, Mann K: The amino acid sequences of human and pig L-arginine:glycine amidinotransferase. FEBS Lett. 1994 Feb 14;339(1-2):101-7.
9148748	Humm A, Fritsche E, Mann K, Gohl M, Huber R: Recombinant expression and isolation of human L-arginine:glycine amidinotransferase and identification of its active-site cysteine residue. Biochem J. 1997 Mar 15;322 ( Pt 3):771-6.
9165070	Humm A, Fritsche E, Steinbacher S: Structure and reaction mechanism of L-arginine:glycine amidinotransferase. Biol Chem. 1997 Mar-Apr;378(3-4):193-7.
9218780	Humm A, Fritsche E, Steinbacher S, Huber R: Crystal structure and mechanism of human L-arginine:glycine amidinotransferase: a mitochondrial enzyme involved in creatine biosynthesis. EMBO J. 1997 Jun 16;16(12):3373-85.
9915841	Fritsche E, Humm A, Huber R: The ligand-induced structural changes of human L-Arginine:Glycine amidinotransferase. A mutational and crystallographic study. J Biol Chem. 1999 Jan 29;274(5):3026-32.

# Drug_Target_13_HGNC_ID:
HGNC:4175

# Drug_Target_13_HPRD_ID:
03838

# Drug_Target_13_ID:
383

# Drug_Target_13_Locus:
15q21.1

# Drug_Target_13_Molecular_Weight:
48456

# Drug_Target_13_Name:
Glycine amidinotransferase, mitochondrial

# Drug_Target_13_Number_of_Residues:
423

# Drug_Target_13_PDB_ID:
3JDW

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF02274	Amidinotransf

# Drug_Target_13_Protein_Sequence:
>Glycine amidinotransferase, mitochondrial precursor
MLRVRCLRGGSRGAEAVHYIGSRLGRTLTGWVQRTFQSTQAATASSRNSCAADDKATEPL
PKDCPVSSYNEWDPLEEVIVGRAENACVPPFTIEVKANTYEKYWPFYQKQGGHYFPKDHL
KKAVAEIEEMCNILKTEGVTVRRPDPIDWSLKYKTPDFESTGLYSAMPRDILIVVGNEII
EAPMAWRSRFFEYRAYRSIIKDYFHRGAKWTTAPKPTMADELYNQDYPIHSVEDRHKLAA
QGKFVTTEFEPCFDAADFIRAGRDIFAQRSQVTNYLGIEWMRRHLAPDYRVHIISFKDPN
PMHIDATFNIIGPGIVLSNPDRPCHQIDLFKKAGWTIITPPTPIIPDDHPLWMSSKWLSM
NVLMLDEKRVMVDANEVPIQKMFEKLGITTIKVNIRNANSLGGGFHCWTCDVRRRGTLQS
YLD

# Drug_Target_13_Reaction:
L-arginine + glycine = L-ornithine + guanidinoacetate

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
Not Available

# Drug_Target_13_SwissProt_ID:
P50440

# Drug_Target_13_SwissProt_Name:
GATM_HUMAN

# Drug_Target_13_Synonyms:
AT
EC 2.1.4.1
Glycine amidinotransferase, mitochondrial precursor
L- arginine:glycine amidinotransferase
Transamidinase

# Drug_Target_13_Theoretical_pI:
8.15

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Nucleus

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
OAZ3

# Drug_Target_14_GenBank_ID_Gene:
AF175296

# Drug_Target_14_GenBank_ID_Protein:
5802609

# Drug_Target_14_GeneCard_ID:
OAZ3

# Drug_Target_14_Gene_Name:
OAZ3

# Drug_Target_14_Gene_Sequence:
>564 bp
ATGCTGCCTCGTTGTTATAAAAGCATCACTTATAAGGAAGAGGAGGACTTGACACTCCAG
CCCCGTTCCTGCCTCCAGTGCTCTGAGTCCCTAGTAGGCCTCCAGGAGGGCAAAAGCACC
GAGCAGGGTAACCACGACCAGCTTAAAGAACTGTATTCGGCTGGGAACTTGACGGTGCTG
GCTACTGACCCCCTGCTCCACCAGGACCCAGTACAGTTAGACTTTCACTTCCGCCTTACC
TCCCAGACCTCTGCCCATTGGCACGGCCTTCTCTGTGACCGTCGACTCTTCCTGGATATC
CCATATCAGGCCTTGGATCAAGGCAACCGGGAAAGTTTGACTGCAACCCTGGAGTACGTG
GAAGAGAAGACAAATGTGGACTCTGTGTTTGTGAACTTCCAGAATGATCGGAACGACAGA
GGTGCCCTGCTGCGGGCCTTCAGCTACATGGGCTTTGAGGTGGTCAGACCAGATCACCCT
GCCCTCCCTCCCTTGGACAATGTCATCTTTATGGTGTATCCCCTTGAAAGGGATGTTGGC
CACCTGCCCAGTGAGCCTCCTTGA

# Drug_Target_14_General_Function:
Not Available

# Drug_Target_14_General_References:
10781085	Ivanov IP, Rohrwasser A, Terreros DA, Gesteland RF, Atkins JF: Discovery of a spermatogenesis stage-specific ornithine decarboxylase antizyme: antizyme 3. Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4808-13.

# Drug_Target_14_HGNC_ID:
HGNC:8097

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
3981

# Drug_Target_14_Locus:
1q21.3

# Drug_Target_14_Molecular_Weight:
21375

# Drug_Target_14_Name:
Ornithine decarboxylase antizyme 3

# Drug_Target_14_Number_of_Residues:
187

# Drug_Target_14_PDB_ID:
Not Available

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF02100	ODC_AZ

# Drug_Target_14_Protein_Sequence:
>Ornithine decarboxylase antizyme 3
MLPRCYKSITYKEEEDLTLQPRSCLQCSESLVGLQEGKSTEQGNHDQLKELYSAGNLTVL
ATDPLLHQDPVQLDFHFRLTSQTSAHWHGLLCDRRLFLDIPYQALDQGNRESLTATLEYV
EEKTNVDSVFVNFQNDRNDRGALLRAFSYMGFEVVRPDHPALPPLDNVIFMVYPLERDVG
HLPSEPP

# Drug_Target_14_Reaction:
Not Available

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
Binds to, and destabilizes, ornithine decarboxylase. Does not accelerate ornithine decarboxylase degeneration. OAZ3 probably plays a key role in spermatogenesis by regulating the intracellular concentration of polyamines in haploid germ cells

# Drug_Target_14_SwissProt_ID:
Q9UMX2

# Drug_Target_14_SwissProt_Name:
OAZ3_HUMAN

# Drug_Target_14_Synonyms:
AZ3
ODC-Az 3

# Drug_Target_14_Theoretical_pI:
4.67

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
15616821	Levillain O, Balvay S, Peyrol S: Localization and differential expression of arginase II in the kidney of male and female mice. Pflugers Arch. 2005 Feb;449(5):491-503. Epub 2004 Dec 23.
16179747	Inubushi T, Takasawa T, Tuboi Y, Watanabe N, Aki K, Katunuma N: Changes of glucose metabolism and skin-collagen neogenesis in vitamin B6 deficiency. Biofactors. 2005;23(2):59-67.
17197567	Kaneko S, Ueda-Yamada M, Ando A, Matsumura S, Okuda-Ashitaka E, Matsumura M, Uyama M, Ito S: Cytotoxic effect of spermine on retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2007 Jan;48(1):455-63.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
OAT

# Drug_Target_1_GenBank_ID_Gene:
M12267

# Drug_Target_1_GenBank_ID_Protein:
189329

# Drug_Target_1_GeneCard_ID:
OAT

# Drug_Target_1_Gene_Name:
OAT

# Drug_Target_1_Gene_Sequence:
>1320 bp
ATGTTTTCCAAACTAGCACATTTGCAGAGGTTTGCTGTACTTAGTCGCGGAGTTCATTCT
TCAGTGGCTTCTGCTACATCTGTTGCAACTAAAAAAACAGTCCAAGGCCCTCCAACCTCT
GATGACATTTTTGAAAGGGAATATAAGTATGGTGCACACAACTACCATCCTTTACCTGTA
GCCCTGGAGAGAGGAAAAGGTATTTACTTATGGGATGTAGAAGGCAGAAAATATTTTGAC
TTCCTGAGTTCTTACAGTGCTGTCAACCAAGGGCATTGTCACCCCAAGATTGTGAATGCT
CTGAAGAGTCAAGTGGACAAATTGACCTTAACATCTAGAGCTTTCTATAATAACGTACTT
GGTGAATATGAGGAGTATATTACTAAACTTTTCAACTACCACAAAGTTCTTCCTATGAAT
ACAGGAGTGGAGGCTGGAGAGACTGCCTGTAAACTAGCTCGTAAGTGGGGCTATACCGTG
AAGGGCATTCAGAAATACAAAGCAAAGATTGTTTTTGCAGCTGGGAACTTCTGGGGTAGG
ACGTTGTCTGCTATCTCCAGTTCCACAGACCCAACCAGTTACGATGGTTTTGGACCATTT
ATGCCGGGATTCGACATCATTCCCTATAATGATCTGCCCGCACTGGAGCGTGCTCTTCAG
GATCCAAATGTGGCTGCGTTCATGGTAGAACCAATTCAGGGTGAAGCAGGCGTTGTTGTT
CCGGATCCAGGTTACCTAATGGGAGTGCGAGAGCTCTGCACCAGGCACCAGGTTCTCTTT
ATTGCTGATGAAATACAGACAGGATTGGCCAGAACTGGTAGATGGCTGGCTGTTGATTAT
GAAAATGTCAGACCTGATATAGTCCTCCTTGGAAAGGCCCTTTCTGGGGGCTTATACCCT
GTGTCTGCAGTGCTGTGTGATGATGACATCATGCTGACCATTAAGCCAGGGGAGCATGGG
TCCACATACGGTGGCAATCCACTAGGCTGCCGAGTGGCCATCGCAGCCCTTGAGGTTTTA
GAAGAAGAAAACCTTGCTGAAAATGCAGACAAATTGGGCATTATCTTGAGAAATGAACTC
ATGAAGCTACCTTCTGATGTTGTAACTGCCGTAAGAGGAAAAGGATTATTAAACGCTATT
GTCATTAAAGAAACCAAAGATTGGGATGCTTGGAAGGTGTGTCTACGACTTCGAGATAAT
GGACTTCTGGCCAAGCCAACCCATGGCGACATTATCAGGTTTGCGCCTCCGCTGGTGATC
AAGGAGGATGAGCTTCGAGAGTCCATTGAAATTATTAACAAGACCATCTTGTCTTTCTGA

# Drug_Target_1_General_Function:
Amino acid transport and metabolism

# Drug_Target_1_General_References:
1612597	Michaud J, Brody LC, Steel G, Fontaine G, Martin LS, Valle D, Mitchell G: Strand-separating conformational polymorphism analysis: efficacy of detection of point mutations in the human ornithine delta-aminotransferase gene. Genomics. 1992 Jun;13(2):389-94.
1682785	Ramesh V, Gusella JF, Shih VE: Molecular pathology of gyrate atrophy of the choroid and retina due to ornithine aminotransferase deficiency. Mol Biol Med. 1991 Feb;8(1):81-93.
1737786	Brody LC, Mitchell GA, Obie C, Michaud J, Steel G, Fontaine G, Robert MF, Sipila I, Kaiser-Kupfer M, Valle D: Ornithine delta-aminotransferase mutations in gyrate atrophy. Allelic heterogeneity and functional consequences. J Biol Chem. 1992 Feb 15;267(5):3302-7.
2373169	Zintz CB, Inana G: Analysis of the human ornithine aminotransferase gene family. Exp Eye Res. 1990 Jun;50(6):759-70.
2507357	Kobayashi T, Nishii M, Takagi Y, Titani K, Matsuzawa T: Molecular cloning and nucleotide sequence analysis of mRNA for human kidney ornithine aminotransferase. An examination of ornithine aminotransferase isozymes between liver and kidney. FEBS Lett. 1989 Sep 25;255(2):300-4.
2793865	Inana G, Chambers C, Hotta Y, Inouye L, Filpula D, Pulford S, Shiono T: Point mutation affecting processing of the ornithine aminotransferase precursor protein in gyrate atrophy. J Biol Chem. 1989 Oct 15;264(29):17432-6.
3170546	Mitchell GA, Looney JE, Brody LC, Steel G, Suchanek M, Engelhardt JF, Willard HF, Valle D: Human ornithine-delta-aminotransferase. cDNA cloning and analysis of the structural gene. J Biol Chem. 1988 Oct 5;263(28):14288-95.
3375240	Ramesh V, McClatchey AI, Ramesh N, Benoit LA, Berson EL, Shih VE, Gusella JF: Molecular basis of ornithine aminotransferase deficiency in B-6-responsive and -nonresponsive forms of gyrate atrophy. Proc Natl Acad Sci U S A. 1988 Jun;85(11):3777-80.
3456579	Inana G, Totsuka S, Redmond M, Dougherty T, Nagle J, Shiono T, Ohura T, Kominami E, Katunuma N: Molecular cloning of human ornithine aminotransferase mRNA. Proc Natl Acad Sci U S A. 1986 Mar;83(5):1203-7.
3754226	Simmaco M, John RA, Barra D, Bossa F: The primary structure of ornithine aminotransferase. Identification of active-site sequence and site of post-translational proteolysis. FEBS Lett. 1986 Apr 7;199(1):39-42.
3816496	Ramesh V, Shaffer MM, Allaire JM, Shih VE, Gusella JF: Investigation of gyrate atrophy using a cDNA clone for human ornithine aminotransferase. DNA. 1986 Dec;5(6):493-501.
7668253	Kobayashi T, Ogawa H, Kasahara M, Shiozawa Z, Matsuzawa T: A single amino acid substitution within the mature sequence of ornithine aminotransferase obstructs mitochondrial entry of the precursor. Am J Hum Genet. 1995 Aug;57(2):284-91.
7887415	Michaud J, Thompson GN, Brody LC, Steel G, Obie C, Fontaine G, Schappert K, Keith CG, Valle D, Mitchell GA: Pyridoxine-responsive gyrate atrophy of the choroid and retina: clinical and biochemical correlates of the mutation A226V. Am J Hum Genet. 1995 Mar;56(3):616-22.
9309222	Shah SA, Shen BW, Brunger AT: Human ornithine aminotransferase complexed with L-canaline and gabaculine: structural basis for substrate recognition. Structure. 1997 Aug 15;5(8):1067-75.
9514741	Shen BW, Hennig M, Hohenester E, Jansonius JN, Schirmer T: Crystal structure of human recombinant ornithine aminotransferase. J Mol Biol. 1998 Mar 20;277(1):81-102.
9878407	Storici P, Capitani G, Muller R, Schirmer T, Jansonius JN: Crystal structure of human ornithine aminotransferase complexed with the highly specific and potent inhibitor 5-fluoromethylornithine. J Mol Biol. 1999 Jan 8;285(1):297-309.

# Drug_Target_1_HGNC_ID:
HGNC:8091

# Drug_Target_1_HPRD_ID:
02021

# Drug_Target_1_ID:
472

# Drug_Target_1_Locus:
10q26

# Drug_Target_1_Molecular_Weight:
48535

# Drug_Target_1_Name:
Ornithine aminotransferase, mitochondrial

# Drug_Target_1_Number_of_Residues:
439

# Drug_Target_1_PDB_ID:
1OAT

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00202	Aminotran_3

# Drug_Target_1_Protein_Sequence:
>Ornithine aminotransferase, mitochondrial precursor
MFSKLAHLQRFAVLSRGVHSSVASATSVATKKTVQGPPTSDDIFEREYKYGAHNYHPLPV
ALERGKGIYLWDVEGRKYFDFLSSYSAVNQGHCHPKIVNALKSQVDKLTLTSRAFYNNVL
GEYEEYITKLFNYHKVLPMNTGVEAGETACKLARKWGYTVKGIQKYKAKIVFAAGNFWGR
TLSAISSSTDPTSYDGFGPFMPGFDIIPYNDLPALERALQDPNVAAFMVEPIQGEAGVVV
PDPGYLMGVRELCTRHQVLFIADEIQTGLARTGRWLAVDYENVRPDIVLLGKALSGGLYP
VSAVLCDDDIMLTIKPGEHGSTYGGNPLGCRVAIAALEVLEEENLAENADKLGIILRNEL
MKLPSDVVTAVRGKGLLNAIVIKETKDWDAWKVCLRLRDNGLLAKPTHGDIIRFAPPLVI
KEDELRESIEIINKTILSF

# Drug_Target_1_Reaction:
L-ornithine + a 2-oxo acid = L-glutamate 5-semialdehyde + an L-amino acid

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P04181

# Drug_Target_1_SwissProt_Name:
OAT_HUMAN

# Drug_Target_1_Synonyms:
EC 2.6.1.13
Ornithine aminotransferase, mitochondrial precursor
Ornithine--oxo-acid aminotransferase

# Drug_Target_1_Theoretical_pI:
7.05

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
12399499	Barcelona-Andres B, Marina A, Rubio V: Gene structure, organization, expression, and potential regulatory mechanisms of arginine catabolism in Enterococcus faecalis. J Bacteriol. 2002 Nov;184(22):6289-300.
12679340	El Alami M, Dubois E, Oudjama Y, Tricot C, Wouters J, Stalon V, Messenguy F: Yeast epiarginase regulation, an enzyme-enzyme activity control: identification of residues of ornithine carbamoyltransferase and arginase responsible for enzyme catalytic and regulatory activities. J Biol Chem. 2003 Jun 13;278(24):21550-8. Epub 2003 Apr 4.
15766270	Templeton MD, Reinhardt LA, Collyer CA, Mitchell RE, Cleland WW: Kinetic analysis of the L-ornithine transcarbamoylase from Pseudomonas savastanoi pv. phaseolicola that is resistant to the transition state analogue (R)-N delta-(N'-sulfodiaminophosphinyl)-L-ornithine. Biochemistry. 2005 Mar 22;44(11):4408-15.
16585758	Morizono H, Cabrera-Luque J, Shi D, Gallegos R, Yamaguchi S, Yu X, Allewell NM, Malamy MH, Tuchman M: Acetylornithine transcarbamylase: a novel enzyme in arginine biosynthesis. J Bacteriol. 2006 Apr;188(8):2974-82.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
OTC

# Drug_Target_2_GenBank_ID_Gene:
K02100

# Drug_Target_2_GenBank_ID_Protein:
189407

# Drug_Target_2_GeneCard_ID:
OTC

# Drug_Target_2_Gene_Name:
OTC

# Drug_Target_2_Gene_Sequence:
>1065 bp
ATGCTGTTTAATCTGAGGATCCTGTTAAACAATGCAGCTTTTAGAAATGGTCACAACTTC
ATGGTTCGAAATTTTCGGTGTGGACAACCACTACAAAATAAAGTGCAGCTGAAGGGCCGT
GACCTTCTCACTCTAAAAAACTTTACCGGAGAAGAAATTAAATATATGCTATGGCTATCA
GCAGATCTGAAATTTAGGATAAAACAGAAAGGAGAGTATTTGCCTTTATTGCAGGGGAAG
TCCTTAGGCATGATTTTTGAGAAAAGAAGTACTCGAACAAGATTGTCTACAGAAACAGGC
TTTGCACTTCTGGGAGGACATCCTTGTTTTCCTACCACACAAGATATTCATTTGGGTGTG
AATGAAAGTCTCACGGACACGGCCCGTGTATTGTCTAGCATGGCAGATGCAGTATTGGCT
CGAGTGTATAAACAATCAGATTTGGACACCCTTGCTAAAGAAGCATCCATCCCAATTATC
AATGGGCTGTCAGATTTGTACCATCCTATCCAGATCCTGGCTGATTACCTCACGCTCCAG
GAACACTATAGCTCTCTGAAAGGTCTTACCCTCAGCTGTTTCGGGGATGGGAACAATATC
CTGCACTCCATCATGATGAGCGCAGCGAAATTCGGAATGCACCTTCAGGCAGCTACTCCA
AAGGGTTATGAGCCGGATGCTAGTGTAACCAAGTTGGCAGAGCAGTATGCCAAAGAGAAT
GGTACCAAGCTGTTGCTGACAAATGATCCATTGGAAGCAGCGCATGGAGGCAATGTATTA
ATTACAGACACTTGGATAAGCATGGGACGAGAAGAGGAGAAGAAAAAGCGGCTCCAAGCT
TTCCAAGGTTACCAAGTTACAATGAAGACTGCTAAAGTTGCTGCCTCTGACTGGACATTT
TTACACTGCTTGCCCAGAAAGCCAGAAGAAGTGGATGATGAAGTCTTTTATTCTCCTCGA
TCACTAGTGTTCCCAGAGGCAGAAAACAGAAAGTGGACAATCATGGCTGTCATGGTGTCC
CTGCTGACAGATTACTCACCTCAGCTCCAGAAGCCTAAATTTTGA

# Drug_Target_2_General_Function:
Amino acid transport and metabolism

# Drug_Target_2_General_References:
10070627	Popowska E, Ciara E, Rokicki D, Pronicka E: Three novel and one recurrent ornithine carbamoyltransferase gene mutations in Polish patients. J Inherit Metab Dis. 1999 Feb;22(1):92-3.
10502831	Climent C, Garcia-Perez MA, Sanjurjo P, Ruiz-Sanz JI, Vilaseca MA, Pineda M, Campistol J, Rubio V: Identification of a cytogenetic deletion and of four novel mutations (Q69X, I172F, G188V, G197R) affecting the gene for ornithine transcarbamylase (OTC) in Spanish patients with OTC deficiency. Hum Mutat. 1999 Oct;14(4):352-3.
10737985	Giorgi M, Morrone A, Donati MA, Ciani F, Bardelli T, Biasucci G, Zammarchi E: Lymphocyte mRNA analysis of the ornithine transcarbamylase gene in Italian OTCD male patients and manifesting carriers: identification of novel mutations. Hum Mutat. 2000 Apr;15(4):380-1.
10813810	Shi D, Morizono H, Aoyagi M, Tuchman M, Allewell NM: Crystal structure of human ornithine transcarbamylase complexed with carbamoyl phosphate and L-norvaline at 1.9 A resolution. Proteins. 2000 Jun 1;39(4):271-7.
11793483	Climent C, Rubio V: Identification of seven novel missense mutations, two splice-site mutations, two microdeletions and a polymorphic amino acid substitution in the gene for ornithine transcarbamylase (OTC) in patients with OTC deficiency. Hum Mutat. 2002 Feb;19(2):185-6.
1480464	Tuchman M, Holzknecht RA, Gueron AB, Berry SA, Tsai MY: Six new mutations in the ornithine transcarbamylase gene detected by single-strand conformational polymorphism. Pediatr Res. 1992 Nov;32(5):600-4.
1671317	Grompe M, Caskey CT, Fenwick RG: Improved molecular diagnostics for ornithine transcarbamylase deficiency. Am J Hum Genet. 1991 Feb;48(2):212-22.
1721894	Hentzen D, Pelet A, Feldman D, Rabier D, Berthelot J, Munnich A: Fatal hyperammonemia resulting from a C-to-T mutation at a MspI site of the ornithine transcarbamylase gene. Hum Genet. 1991 Dec;88(2):153-6.
2347583	Finkelstein JE, Francomano CA, Brusilow SW, Traystman MD: Use of denaturing gradient gel electrophoresis for detection of mutation and prospective diagnosis in late onset ornithine transcarbamylase deficiency. Genomics. 1990 Jun;7(2):167-72.
2474822	Grompe M, Muzny DM, Caskey CT: Scanning detection of mutations in human ornithine transcarbamoylase by chemical mismatch cleavage. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5888-92.
2836378	Hata A, Tsuzuki T, Shimada K, Takiguchi M, Mori M, Matsuda I: Structure of the human ornithine transcarbamylase gene. J Biochem (Tokyo). 1988 Feb;103(2):302-8.
3170748	Maddalena A, Spence JE, O'Brien WE, Nussbaum RL: Characterization of point mutations in the same arginine codon in three unrelated patients with ornithine transcarbamylase deficiency. J Clin Invest. 1988 Oct;82(4):1353-8.
3782067	Hata A, Tsuzuki T, Shimada K, Takiguchi M, Mori M, Matsuda I: Isolation and characterization of the human ornithine transcarbamylase gene: structure of the 5'-end region. J Biochem (Tokyo). 1986 Sep;100(3):717-25.
3895227	Horwich AL, Kalousek F, Rosenberg LE: Arginine in the leader peptide is required for both import and proteolytic cleavage of a mitochondrial precursor. Proc Natl Acad Sci U S A. 1985 Aug;82(15):4930-3.
6372096	Horwich AL, Fenton WA, Williams KR, Kalousek F, Kraus JP, Doolittle RF, Konigsberg W, Rosenberg LE: Structure and expression of a complementary DNA for the nuclear coded precursor of human mitochondrial ornithine transcarbamylase. Science. 1984 Jun 8;224(4653):1068-74.
7474905	Zimmer KP, Matsuura T, Colombo JP, Koch HG, Ullrich K, Deufel T, Harms E, Matsuda I: A novel point mutation at codon 269 of the ornithine transcarbamylase (OTC) gene causing neonatal onset of OTC deficiency. J Inherit Metab Dis. 1995;18(3):356-7.
7627182	Tuchman M, Plante RJ: Mutations and polymorphisms in the human ornithine transcarbamylase gene: mutation update addendum. Hum Mutat. 1995;5(4):293-5.
7951259	Tuchman M, Plante RJ, McCann MT, Qureshi AA: Seven new mutations in the human ornithine transcarbamylase gene. Hum Mutat. 1994;4(1):57-60.
8019569	Tuchman M, Plante RJ, Giguere Y, Lemieux B: The ornithine transcarbamylase gene: new "private" mutations in four patients and study of a polymorphism. Hum Mutat. 1994;3(3):318-20.
8081373	Gilbert-Dussardier B, Rabier D, Strautnieks S, Segues B, Bonnefont JP, Munnich A: A novel arginine (245) to glutamine change in exon 8 of the ornithine carbamoyl transferase gene in two unrelated children presenting with late onset deficiency and showing the same enzymatic pattern. Hum Mol Genet. 1994 May;3(5):831-2.
8081398	Matsuura T, Hoshide R, Kiwaki K, Komaki S, Koike E, Endo F, Oyanagi K, Suzuki Y, Kato I, Ishikawa K, et al.: Four newly identified ornithine transcarbamylase (OTC) mutations (D126G, R129H, I172M and W332X) in Japanese male patients with early-onset OTC deficiency. Hum Mutat. 1994;3(4):402-6.
8099056	Tsai MY, Holzknecht RA, Tuchman M: Single-strand conformational polymorphism and direct sequencing applied to carrier testing in families with ornithine transcarbamylase deficiency. Hum Genet. 1993 May;91(4):321-5.
8364586	Tuchman M: Mutations and polymorphisms in the human ornithine transcarbamylase gene. Hum Mutat. 1993;2(3):174-8.
8530002	Garcia-Perez MA, Paz Briones PS, Garcia-Munnoz MJ, Rubio V: A splicing mutation, a nonsense mutation (Y167X) and two missense mutations (I159T and A209V) in Spanish patients with ornithine transcarbamylase deficiency. Hum Genet. 1995 Nov;96(5):549-51.
8544185	Tuchman M, Morizono H, Reish O, Yuan X, Allewell NM: The molecular basis of ornithine transcarbamylase deficiency: modelling the human enzyme and the effects of mutations. J Med Genet. 1995 Sep;32(9):680-8.
8807340	Gilbert-Dussardier B, Segues B, Rozet JM, Rabier D, Calvas P, de Lumley L, Bonnefond JP, Munnich A: Partial duplication [dup. TCAC (178)] and novel point mutations (T125M, G188R, A209V, and H302L) of the ornithine transcarbamylase gene in congenital hyperammonemia. Hum Mutat. 1996;8(1):74-6.
8830175	Yoo HW, Kim GH, Lee DH: Identification of new mutations in the ornithine transcarbamylase (OTC) gene in Korean families. J Inherit Metab Dis. 1996;19(1):31-42.
8956038	Oppliger Leibundgut EO, Wermuth B, Colombo JP, Liechti-Gallati S: Ornithine transcarbamylase deficiency: characterization of gene mutations and polymorphisms. Hum Mutat. 1996;8(4):333-9.
8956045	Segues B, Veber PS, Rabier D, Calvas P, Saudubray JM, Gilbert-Dussardier B, Bonnefont JP, Munnich A: A 3-base pair in-frame deletion in exon 8 (delGlu272/273) of the ornithine transcarbamylase gene in late-onset hyperammonemic coma. Hum Mutat. 1996;8(4):373-4.
9065786	Morizono H, Tuchman M, Rajagopal BS, McCann MT, Listrom CD, Yuan X, Venugopal D, Barany G, Allewell NM: Expression, purification and kinetic characterization of wild-type human ornithine transcarbamylase and a recurrent mutant that produces 'late onset' hyperammonaemia. Biochem J. 1997 Mar 1;322 ( Pt 2):625-31.
9143919	Oppliger Leibundgut E, Liechti-Gallati S, Colombo JP, Wermuth B: Ornithine transcarbamylase deficiency: ten new mutations and high proportion of de novo mutations in heterozygous females. Hum Mutat. 1997;9(5):409-11.
9266388	Tuchman M, Morizono H, Rajagopal BS, Plante RJ, Allewell NM: Identification of 'private' mutations in patients with ornithine transcarbamylase deficiency. J Inherit Metab Dis. 1997 Aug;20(4):525-7.
9286441	Matsuda I, Tanase S: The ornithine transcarbamylase (OTC) gene: mutations in 50 Japanese families with OTC deficiency. Am J Med Genet. 1997 Sep 5;71(4):378-83.
9452024	Shimadzu M, Matsumoto H, Matsuura T, Kobayashi K, Komaki S, Kiwaki K, Hoshide R, Endo F, Saheki T, Matsuda I: Ten novel mutations of the ornithine transcarbamylase (OTC) gene in OTC deficiency. Hum Mutat. 1998;Suppl 1:S5-7.
9452049	Calvas P, Segues B, Rozet JM, Rabier D, Bonnefond JP, Munnich A: Novel intragenic deletions and point mutations of the ornithine transcarbamylase gene in congenital hyperammonemia. Hum Mutat. 1998;Suppl 1:S81-4.
9452065	Nishiyori A, Yoshino M, Tananari Y, Matsuura T, Hoshide R, Mastuda I, Mori M, Kato H: Y55D mutation in ornithine transcarbamylase associated with late-onset hyperammonemia in a male. Hum Mutat. 1998;Suppl 1:S131-3.
9852088	Shi D, Morizono H, Ha Y, Aoyagi M, Tuchman M, Allewell NM: 1.85-A resolution crystal structure of human ornithine transcarbamoylase complexed with N-phosphonacetyl-L-ornithine. Catalytic mechanism and correlation with inherited deficiency. J Biol Chem. 1998 Dec 18;273(51):34247-54.

# Drug_Target_2_HGNC_ID:
HGNC:8512

# Drug_Target_2_HPRD_ID:
08947

# Drug_Target_2_ID:
336

# Drug_Target_2_Locus:
Xp21.1

# Drug_Target_2_Molecular_Weight:
39936

# Drug_Target_2_Name:
Ornithine carbamoyltransferase, mitochondrial

# Drug_Target_2_Number_of_Residues:
354

# Drug_Target_2_PDB_ID:
1FVO

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00185	OTCace
PF02729	OTCace_N

# Drug_Target_2_Protein_Sequence:
>Ornithine carbamoyltransferase, mitochondrial precursor
MLFNLRILLNNAAFRNGHNFMVRNFRCGQPLQNKVQLKGRDLLTLKNFTGEEIKYMLWLS
ADLKFRIKQKGEYLPLLQGKSLGMIFEKRSTRTRLSTETGFALLGGHPCFLTTQDIHLGV
NESLTDTARVLSSMADAVLARVYKQSDLDTLAKEASIPIINGLSDLYHPIQILADYLTLQ
EHYSSLKGLTLSWIGDGNNILHSIMMSAAKFGMHLQAATPKGYEPDASVTKLAEQYAKEN
GTKLLLTNDPLEAAHGGNVLITDTWISMGQEEEKKKRLQAFQGYQVTMKTAKVAASDWTF
LHCLPRKPEEVDDEVFYSPRSLVFPEAENRKWTIMAVMVSLLTDYSPQLQKPKF

# Drug_Target_2_Reaction:
carbamoyl phosphate + L-ornithine = phosphate + L-citrulline

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P00480

# Drug_Target_2_SwissProt_Name:
OTC_HUMAN

# Drug_Target_2_Synonyms:
EC 2.1.3.3
OTCase
Ornithine carbamoyltransferase, mitochondrial precursor
Ornithine transcarbamylase

# Drug_Target_2_Theoretical_pI:
8.96

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasm

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
11971019	Gobert AP, Cheng Y, Wang JY, Boucher JL, Iyer RK, Cederbaum SD, Casero RA Jr, Newton JC, Wilson KT: Helicobacter pylori induces macrophage apoptosis by activation of arginase II. J Immunol. 2002 May 1;168(9):4692-700.
12135320	Iwata S, Tsujino T, Ikeda Y, Ishida T, Ueyama T, Gotoh T, Mori M, Yokoyama M: Decreased expression of arginase II in the kidneys of Dahl salt-sensitive rats. Hypertens Res. 2002 May;25(3):411-8.
12446178	Stickings P, Mistry SK, Boucher JL, Morris SM, Cunningham JM: Arginase expression and modulation of IL-1beta-induced nitric oxide generation in rat and human islets of Langerhans. Nitric Oxide. 2002 Dec;7(4):289-96.
12589193	Bansal V, Ochoa JB: Arginine availability, arginase, and the immune response. Curr Opin Clin Nutr Metab Care. 2003 Mar;6(2):223-8.
12679340	El Alami M, Dubois E, Oudjama Y, Tricot C, Wouters J, Stalon V, Messenguy F: Yeast epiarginase regulation, an enzyme-enzyme activity control: identification of residues of ornithine carbamoyltransferase and arginase responsible for enzyme catalytic and regulatory activities. J Biol Chem. 2003 Jun 13;278(24):21550-8. Epub 2003 Apr 4.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
ARG1

# Drug_Target_3_GenBank_ID_Gene:
M14502

# Drug_Target_3_GenBank_ID_Protein:
178995

# Drug_Target_3_GeneCard_ID:
ARG1

# Drug_Target_3_Gene_Name:
ARG1

# Drug_Target_3_Gene_Sequence:
>969 bp
ATGAGCGCCAAGTCCAGAACCATAGGGATTATTGGAGCTCCTTTCTCAAAGGGACAGCCA
CGAGGAGGGGTGGAAGAAGGCCCTACAGTATTGAGAAAGGCTGGTCTGCTTGAGAAACTT
AAAGAACAAGAGTGTGATGTGAAGGATTATGGGGACCTGCCCTTTGCTGACATCCCTAAT
GACAGTCCCTTTCAAATTGTGAAGAATCCAAGGTCTGTGGGAAAAGCAAGCGAGCAGCTG
GCTGGCAAGGTGGCACAAGTCAAGAAGAACGGAAGAATCAGCCTGGTGCTGGGCGGAGAC
CACAGTTTGGCAATTGGAAGCATCTCTGGCCATGCCAGGGTCCACCCTGATCTTGGAGTC
ATCTGGGTGGATGCTCACACTGATATCAACACTCCACTGACAACCACAAGTGGAAACTTG
CATGGACAACCTGTATCTTTCCTCCTGAAGGAACTAAAAGGAAAGATTCCCGATGTGCCA
GGATTCTCCTGGGTGACTCCCTGTATATCTGCCAAGGATATTGTGTATATTGGCTTGAGA
GACGTGGACCCTGGGGAACACTACATTTTGAAAACTCTAGGCATTAAATACTTTTCAATG
ACTGAAGTGGACAGACTAGGAATTGGCAAGGTGATGGAAGAAACACTCAGCTATCTACTA
GGAAGAAAGAAAAGGCCAATTCATCTAAGTTTTGATGTTGACGGACTGGACCCATCTTTC
ACACCAGCTACTGGCACACCAGTCGTGGGAGGTCTGACATACAGAGAAGGTCTCTACATC
ACAGAAGAAATCTACAAAACAGGGCTACTCTCAGGATTAGATATAATGGAAGTGAACCCA
TCCCTGGGGAAGACACCAGAAGAAGTAACTCGAACAGTGAACACAGCAGTTGCAATAACC
TTGGCTTGTTTCGGACTTGCTCGGGAGGGTAATCACAAGCCTATTGACTACCTTAACCCA
CCTAAGTAA

# Drug_Target_3_General_Function:
Amino acid transport and metabolism

# Drug_Target_3_General_References:
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
1463019	Uchino T, Haraguchi Y, Aparicio JM, Mizutani N, Higashikawa M, Naitoh H, Mori M, Matsuda I: Three novel mutations in the liver-type arginase gene in three unrelated Japanese patients with argininemia. Am J Hum Genet. 1992 Dec;51(6):1406-12.
1598908	Grody WW, Klein D, Dodson AE, Kern RM, Wissmann PB, Goodman BK, Bassand P, Marescau B, Kang SS, Leonard JV, et al.: Molecular genetic study of human arginase deficiency. Am J Hum Genet. 1992 Jun;50(6):1281-90.
2241902	Ikemoto M, Tabata M, Miyake T, Kono T, Mori M, Totani M, Murachi T: Expression of human liver arginase in Escherichia coli. Purification and properties of the product. Biochem J. 1990 Sep 15;270(3):697-703.
3174433	Takiguchi M, Haraguchi Y, Mori M: Human liver-type arginase gene: structure of the gene and analysis of the promoter region. Nucleic Acids Res. 1988 Sep 26;16(18):8789-802.
3540966	Haraguchi Y, Takiguchi M, Amaya Y, Kawamoto S, Matsuda I, Mori M: Molecular cloning and nucleotide sequence of cDNA for human liver arginase. Proc Natl Acad Sci U S A. 1987 Jan;84(2):412-5.
7649538	Uchino T, Snyderman SE, Lambert M, Qureshi IA, Shapira SK, Sansaricq C, Smit LM, Jakobs C, Matsuda I: Molecular basis of phenotypic variation in patients with argininemia. Hum Genet. 1995 Sep;96(3):255-60.

# Drug_Target_3_HGNC_ID:
HGNC:663

# Drug_Target_3_HPRD_ID:
01947

# Drug_Target_3_ID:
315

# Drug_Target_3_Locus:
6q23

# Drug_Target_3_Molecular_Weight:
34735

# Drug_Target_3_Name:
Arginase-1

# Drug_Target_3_Number_of_Residues:
322

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00491	Arginase

# Drug_Target_3_Protein_Sequence:
>Arginase-1
MSAKSRTIGIIGAPFSKGQPRGGVEEGPTVLRKAGLLEKLKEQECDVKDYGDLPFADIPN
DSPFQIVKNPRSVGKASEQLAGKVAEVKKNGRISLVLGGDHSLAIGSISGHARVHPDLGV
IWVDAHTDINTPLTTTSGNLHGQPVSFLLKELKGKIPDVPGFSWVTPCISAKDIVYIGLR
DVDPGEHYILKTLGIKYFSMTEVDRLGIGKVMEETLSYLLGRKKRPIHLSFDVDGLDPSF
TPATGTPVVGGLTYREGLYITEEIYKTGLLSGLDIMEVNPSLGKTPEEVTRTVNTAVAIT
LACFGLAREGNHKPIDYLNPPK

# Drug_Target_3_Reaction:
L-arginine + H2O = L-ornithine + urea

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
P05089

# Drug_Target_3_SwissProt_Name:
ARGI1_HUMAN

# Drug_Target_3_Synonyms:
EC 3.5.3.1
Liver-type arginase
Type I arginase

# Drug_Target_3_Theoretical_pI:
7.25

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
15009201	Janne J, Alhonen L, Pietila M, Keinanen TA: Genetic approaches to the cellular functions of polyamines in mammals. Eur J Biochem. 2004 Mar;271(5):877-94.
16354653	Yamaguchi Y, Takatsuka Y, Matsufuji S, Murakami Y, Kamio Y: Characterization of a counterpart to Mammalian ornithine decarboxylase antizyme in prokaryotes. J Biol Chem. 2006 Feb 17;281(7):3995-4001. Epub 2005 Dec 14.
16916800	Lopez-Contreras AJ, Lopez-Garcia C, Jimenez-Cervantes C, Cremades A, Penafiel R: Mouse ornithine decarboxylase-like gene encodes an antizyme inhibitor devoid of ornithine and arginine decarboxylating activity. J Biol Chem. 2006 Oct 13;281(41):30896-906. Epub 2006 Aug 17.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
OAZ1

# Drug_Target_4_GenBank_ID_Gene:
U09202

# Drug_Target_4_GenBank_ID_Protein:
852429

# Drug_Target_4_GeneCard_ID:
OAZ1

# Drug_Target_4_Gene_Name:
OAZ1

# Drug_Target_4_Gene_Sequence:
>681 bp
AATCCTCCCTGCAGCGGATCCTCAATAGCCACTGCTTCGCCAGAGAGAAGGAAGGGGATA
AACCCAGCGCCACCATCCACGCCAGCCGCACCATGCCGCTCCTTAGCCTGCACAGCCGCG
GCGGCAGCAGCAGTGAGAGTTCCAGGGTCTCCCTCCACTGCTGTAGTAACCCGGGTCCGG
GGCCTCGGTGGTGCTCCTGATGCCCCTCACCCACCCCTGAAGATCCCAGGTGGGCGAGGG
AATAGTCAGAGGGATCACAATCTTTCAGCTAACTTATTCTACTCCGATGATCGGCTGAAT
GTAACAGAGGAACTAACGTCCAACGACAAGACGAGGATTCTCAACGTCCAGTCCAGGCTC
ACAGACGCCAAACGCATTAACTGGCGAACAGTGCTGAGTGGCGGCAGCCTCTACATCGAG
ATCCCGGGCGGCGCGCTGCCCGAGGGGAGCAAGGACAGCTTTGCAGTTCTCCTGGAGTTC
GCTGAGGAGCAGCTGCGAGCCGACCATGTCTTCATTTGCTTCCACAAGAACCGCGAGGAC
AGAGCCGCCTTGCTCCGAACCTTCAGCTTTTTGGGCTTTGAGATTGTGAGACCGGGGCAT
CCCCTTGTCCCCAAGAGACCCGACGCTTGCTTCATGGCCTACACGTTCGAGAGAGAGTCT
TCGGGAGAGGAGGAGGAGTAG

# Drug_Target_4_General_Function:
Involved in enzyme inhibitor activity

# Drug_Target_4_General_References:
7811704	Tewari DS, Qian Y, Thornton RD, Pieringer J, Taub R, Mochan E, Tewari M: Molecular cloning and sequencing of a human cDNA encoding ornithine decarboxylase antizyme. Biochim Biophys Acta. 1994 Dec 14;1209(2):293-5.
9132164	Yang D, Takii T, Hayashi H, Itoh S, Hayashi M, Onozaki K: Molcecular cloning of human antizyme cDNA. Biochem Mol Biol Int. 1996 Apr;38(5):957-64.
9426243	Hayashi T, Matsufuji S, Hayashi S: Characterization of the human antizyme gene. Gene. 1997 Dec 12;203(2):131-9.

# Drug_Target_4_HGNC_ID:
HGNC:8095

# Drug_Target_4_HPRD_ID:
03346

# Drug_Target_4_ID:
410

# Drug_Target_4_Locus:
19p13.3

# Drug_Target_4_Molecular_Weight:
25275

# Drug_Target_4_Name:
Ornithine decarboxylase antizyme

# Drug_Target_4_Number_of_Residues:
227

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF02100	ODC_AZ

# Drug_Target_4_Protein_Sequence:
>Ornithine decarboxylase antizyme
VKSSLQRILNSHCFAREKEGDKPSATIHASRTMPLLSLHSRGGSSSESSRVSLHCCSNPG
PGPRWCSDAPHPPLKIPGGRGNSQRDHNLSANLFYSDDRLNVTEELTSNDKTRILNVQSR
LTDAKRINWRTVLSGGSLYIEIPGGALPEGSKDSFAVLLEFAEEQLRADHVFICFHKNRE
DRAALLRTFSFLGFEIVRPGHPLVPKRPDACFMAYTFERESSGEEEE

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Binds to, and destabilizes, ornithine decarboxylase which is then degraded. Also inhibits cellular uptake of polyamines by inactivating the polyamine uptake transporter

# Drug_Target_4_SwissProt_ID:
P54368

# Drug_Target_4_SwissProt_Name:
OAZ1_HUMAN

# Drug_Target_4_Synonyms:
ODC-Az

# Drug_Target_4_Theoretical_pI:
7.57

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
12679322	Endo M, Oyadomari S, Terasaki Y, Takeya M, Suga M, Mori M, Gotoh T: Induction of arginase I and II in bleomycin-induced fibrosis of mouse lung. Am J Physiol Lung Cell Mol Physiol. 2003 Aug;285(2):L313-21. Epub 2003 Apr 4.
16703566	Yeramian A, Martin L, Arpa L, Bertran J, Soler C, McLeod C, Modolell M, Palacin M, Lloberas J, Celada A: Macrophages require distinct arginine catabolism and transport systems for proliferation and for activation. Eur J Immunol. 2006 Jun;36(6):1516-26.
17065601	Cerec V, Piquet-Pellorce C, Aly HA, Touzalin AM, Jegou B, Bauche F: Multiple pathways for cationic amino Acid transport in rat seminiferous tubule cells. Biol Reprod. 2007 Feb;76(2):241-9. Epub 2006 Oct 25.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
SLC7A2

# Drug_Target_5_GenBank_ID_Gene:
D29990

# Drug_Target_5_GenBank_ID_Protein:
849051

# Drug_Target_5_GeneCard_ID:
SLC7A2

# Drug_Target_5_Gene_Name:
SLC7A2

# Drug_Target_5_Gene_Sequence:
>1977 bp
ATGATTCCTTGCAGAGCCGCGCTGACCTTTGCCCGATGTCTGATCCGGAGAAAAATCGTG
ACCCTGGACAGTCTAGAAGACACCAAATTATGCCGCTGCTTATCCACCATGGACCTCATT
GCCCTGGGCGTTGGAAGCACCCTTGGGGCCGGGGTTTATGTCCTCGCTGGGGAGGTGGCC
AAGGCAGACTCGGGCCCCAGCATCGTGGTGTCCTTCCTCATTGCTGCCCTGGCTTCAGTG
ATGGCTGGCCTCTGCTATGCCGAATTTGGGGCCCGTGTTCCCAAGACGGGGTCTGCATAT
TTGTACACCTACGTGACTGTCGGAGAGCTGTGGGCCTTCATCACTGGCTGGAATCTCATT
TTATCGTATGTGATAGGTACATCAAGTGTTGCAAGAGCCGGGAGTGGCACCTTTGATGAA
CTTCTTAGCAAACAGATTGGTCAGTTTTTGAGGACATACTTCAGAATGAATTACACTGGT
CTTGCAGAATATCCCGATTTTTTTGCTGTGTGCCTTATATTACTTCTAGCAGGTCTTTTG
TCTTTTGGAGTAAAAGAGTCTGCTTGGGTGAATAAAGTCTTCACAGCTGTTAATATTCTC
GTCCTTCTGTTTGTGATGGTTGCTGGGTTTGTGAAAGGAAATGTGGCAAACTGGAAGATT
AGTGAAGAGTTTCTCAAAAATATATCAGCAAGTGCCAGAGAGCCACCTTCTGAAAACGGA
ACAAGTATCTATGGGGCTGGTGGCTTTATGCCTTATGGCTTTACGGGAACGTTGGCTGGT
GCTGCAACTTGCTTTTATGCCTTTGTGGGATTTGACTGCATTGCAACAACTGGTGAAGAA
GTTCGGAATCCCCAGAAAGCTATTCCCATTGGAATTGTGACGTCTTTGCTTGTTTGCTTT
ATGGCCTATTTTGGGGTCTCTGCAGCTTTAACACTTATGATGCCGTACTACCTCCTCGAT
GAAAAAAGCCCCCTTCCTGTAGCGTTTGAATATGTGGGATGGGGTCCTGCCAAATATGTC
GTCGCAGCTGGTTCTCTCTGCGCCTTGTCAACAAGTCTTCTTGGATCCATTTTCCCAATG
CCTCGTGTAAACTATGCTATGGCGGAGGATGGGTTGCTTTTCAAATGTCTAGCTCAAATC
AATTCCAAAACGAAGACACCAATAATTGCTACTTTATCATCGGGTGCAGTGGCAGCTTTG
ATGGCCTTTCTGTTTGACCTGAAGGCGCTTGTGGACATGATGTCCATTGGCACACTCATG
GCCTACTCTCTGGTGGCAGCCTGTGTTCTCATCCTCAGGTACCAGCCTGGCTTATCTTAC
GACCAGCCCAAATGTTCTCCTGAGAAAGATGGTCTGGGATCGTCTCCCAGGGTAACCTCG
AAGAGTGAGTCCCAGGTCACCATGCTGCAGAGACAGGGCTTCAGCATGCGGACCCTCTTC
TGCCCCTCCCTTCTGCCAACACAGCAGTCAGCTTCTCTCGTGAGCTTTCTGGTAGGATTC
CTAGCTTTCCTCGTGTTGGGCCTGAGTGTCTTGACCACTTACGGAGTTCATGCCATCTAC
AGGCTGGAGGCCTGGAGCCTCGCTCTCCTCGCGCTGTTTCTTGTTCTCTTCGTTGCCATC
GTTCTCACCATCTGGAGGCAGCCCCAGAATCAACGAAAAGTAGCCTTCATGGTTCCATTC
TTACCATTTTTGCCGACGTTCACGATCTTGGTGAACATTTACTTGATGGTCCAGTTAAGT
GCAGACACTTGGGTCAGATTCAGCATTTGGATGGCAATTGGCTTCCTGATTTACTTTTCT
TATGGCATTAGACACAGCCTGGAGGGTCATCTGAGAGATGAAAACAATGAAGAAGATGCT
TATCCAGACAACGTTCATGCAGCAGCAGAAGAAAAATCTGCCATTCAAGCAAATGACCAT
CACCCAAGAAATCTCAGTTCACCTTTCATATTCCATGAAAAGACAAGTGAATTCTAA

# Drug_Target_5_General_Function:
Amino acid transport and metabolism

# Drug_Target_5_General_References:
8954799	Hoshide R, Ikeda Y, Karashima S, Matsuura T, Komaki S, Kishino T, Niikawa N, Endo F, Matsuda I: Molecular cloning, tissue distribution, and chromosomal localization of human cationic amino acid transporter 2 (HCAT2). Genomics. 1996 Dec 1;38(2):174-8.

# Drug_Target_5_HGNC_ID:
HGNC:11060

# Drug_Target_5_HPRD_ID:
03524

# Drug_Target_5_ID:
619

# Drug_Target_5_Locus:
8p22-p21.3

# Drug_Target_5_Molecular_Weight:
71680

# Drug_Target_5_Name:
Low-affinity cationic amino acid transporter 2

# Drug_Target_5_Number_of_Residues:
658

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00324	AA_permease

# Drug_Target_5_Protein_Sequence:
>Low-affinity cationic amino acid transporter 2
MIPCRAALTFARCLIRRKIVTLDSLEDTKLCRCLSTMDLIALGVGSTLGAGVYVLAGEVA
KADSGPSIVVSFLIAALASVMAGLCYAEFGARVPKTGSAYLYTYVTVGELWAFITGWNLI
LSYVIGTSSVARAGSGTFDELLSKQIGQFLRTYFRMNYTGLAEYPDFFAVCLILLLAGLL
SFGVKESAWVNKVFTAVNILVLLFVMVAGFVKGNVANWKISEEFLKNISASAREPPSENG
TSIYGAGGFMPYGFTGTLAGAATCFYAFVGFDCIATTGEEVRNPQKAIPIGIVTSLLVCF
MAYFGVSAALTLMMPYYLLDEKSPLPVAFEYVGWGPAKYVVAAGSLCALSTSLLGSIFPM
PRVNYAMAEDGLLFKCLAQINSKTKTPIIATLSSGAVAALMAFLFDLKALVDMMSIGTLM
AYSLVAACVLILRYQPGLSYDQPKCSPEKDGLGSSPRVTSKSESQVTMLQRQGFSMRTLF
CPSLLPTQQSASLVSFLVGFLAFLVLGLSVLTTYGVHAIYRLEAWSLALLALFLVLFVAI
VLTIWRQPQNQRKVAFMVPFLPFLPTFTILVNIYLMVQLSADTWVRFSIWMAIGFLIYFS
YGIRHSLEGHLRDENNEEDAYPDNVHAAAEEKSAIQANDHHPRNLSSPFIFHEKTSEF

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Low-affinity, high capacity permease involved in the transport of the cationic amino acids (arginine, lysine and ornithine)

# Drug_Target_5_SwissProt_ID:
P52569

# Drug_Target_5_SwissProt_Name:
CTR2_HUMAN

# Drug_Target_5_Synonyms:
CAT-2
CAT2

# Drug_Target_5_Theoretical_pI:
7.55

# Drug_Target_5_Transmembrane_Regions:
38-59
64-84
105-125
164-184
193-213
249-269
290-309
340-360
387-407
411-431
491-511
525-549
558-578
583-603

# Drug_Target_6_Cellular_Location:
Mitochondrion
mitochondrial inner membrane
multi-pass membrane protein

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
11997094	Begum L, Jalil MA, Kobayashi K, Iijima M, Li MX, Yasuda T, Horiuchi M, del Arco A, Satrustegui J, Saheki T: Expression of three mitochondrial solute carriers, citrin, aralar1 and ornithine transporter, in relation to urea cycle in mice. Biochim Biophys Acta. 2002 Apr 12;1574(3):283-92.
12948741	Camacho JA, Rioseco-Camacho N, Andrade D, Porter J, Kong J: Cloning and characterization of human ORNT2: a second mitochondrial ornithine transporter that can rescue a defective ORNT1 in patients with the hyperornithinemia-hyperammonemia-homocitrullinuria syndrome, a urea cycle disorder. Mol Genet Metab. 2003 Aug;79(4):257-71.
16940241	Camacho JA, Mardach R, Rioseco-Camacho N, Ruiz-Pesini E, Derbeneva O, Andrade D, Zaldivar F, Qu Y, Cederbaum SD: Clinical and functional characterization of a human ORNT1 mutation (T32R) in the hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome. Pediatr Res. 2006 Oct;60(4):423-9. Epub 2006 Aug 28.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
SLC25A2

# Drug_Target_6_GenBank_ID_Gene:
AF332005

# Drug_Target_6_GenBank_ID_Protein:
13445628

# Drug_Target_6_GeneCard_ID:
SLC25A2

# Drug_Target_6_Gene_Name:
SLC25A2

# Drug_Target_6_Gene_Sequence:
>906 bp
ATGAAGTCCGGTCCTGGCATCCAAGCCGCCATCGACCTCACAGCGGGGGCCGCAGGGGGG
ACAGCGTGTGTACTGACTGGGCAGCCCTTCGACACAATAAAAGTGAAGATGCAGACGTTC
CCTGACCTGTACAAGGGCCTCACCGACTGCTTCCTGAAGACATACGCCCAAGTGGGTCTC
CGGGGCTTCTACAAGGGCACCGGCCCGGCACTTATGGCCTACGTCGCCGAAAACTCGGTC
CTCTTCATGTGCTACGGGTTCTGCCAGCAGTTTGTCAGGAAAGTGGCTGGAATGGACAAG
CAGGCAAAGCTGAGTGATCTCCAGACTGCAGCCGCGGGGTCCTTCGCCTCTGCATTTGCT
GCACTGGCTCTCTGCCCCACTGAGCTTGTGAAGTGCCGGCTACAGACCATGTATGAAATG
GAGATGTCAGGGAAGATAGCAAAAAGCCATAATACAATTTGGTCTGTCGTGAAGGGTATC
CTTAAAAAGGATGGCCCCTTGGGCTTCTACCATGGACTCTCGAGTACTCTACTTCAAGAA
GTACCGGGTTATTTCTTTTTCTTTGGTGGCTATGAACTGAGCCGATCGTTTTTTGCGTCA
GGGAGATCAAAAGATGAACTAGGCCCTGTCCATTTGATGTTAAGTGGTGGAGTTGCTGGA
ATTTGCCTGTGGCTTGTCGTGTTCCCAGTGGATTGTATTAAATCCAGAATTCAAGTTCTT
TCCATGTATGGGAAACAGGCAGGATTTATTGGTACCCTCTTAAGTGTTGTGAGAAATGAA
GGAATAGTAGCCTTATATTCTGGACTGAAAGCTACTATGATTCGAGCAATCCCTGCCAAT
GGGGCACTGTTTGTGGCCTACGAATACAGCAGGAAGATGATGATGAAACAGTTGGAAGCA
TACTGA

# Drug_Target_6_General_Function:
Involved in ornithine transport activity

# Drug_Target_6_General_References:
11230163	Wu Q, Zhang T, Cheng JF, Kim Y, Grimwood J, Schmutz J, Dickson M, Noonan JP, Zhang MQ, Myers RM, Maniatis T: Comparative DNA sequence analysis of mouse and human protocadherin gene clusters. Genome Res. 2001 Mar;11(3):389-404.
12948741	Camacho JA, Rioseco-Camacho N, Andrade D, Porter J, Kong J: Cloning and characterization of human ORNT2: a second mitochondrial ornithine transporter that can rescue a defective ORNT1 in patients with the hyperornithinemia-hyperammonemia-homocitrullinuria syndrome, a urea cycle disorder. Mol Genet Metab. 2003 Aug;79(4):257-71.

# Drug_Target_6_HGNC_ID:
HGNC:22921

# Drug_Target_6_HPRD_ID:
12180

# Drug_Target_6_ID:
285

# Drug_Target_6_Locus:
5q31

# Drug_Target_6_Molecular_Weight:
32553

# Drug_Target_6_Name:
Mitochondrial ornithine transporter 2

# Drug_Target_6_Number_of_Residues:
301

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00153	Mito_carr

# Drug_Target_6_Protein_Sequence:
>Mitochondrial ornithine transporter 2
MKSGPGIQAAIDLTAGAAGGTACVLTGQPFDTIKVKMQTFPDLYKGLTDCFLKTYAQVGL
RGFYKGTGPALMAYVAENSVLFMCYGFCQQFVRKVAGMDKQAKLSDLQTAAAGSFASAFA
ALALCPTELVKCRLQTMYEMEMSGKIAKSHNTIWSVVKGILKKDGPLGFYHGLSSTLLQE
GPGYFFFFGGYELSRSFFASGRSKDELGPVHLMLSGGVAGICLWLIVFPVDCIKSRIQVL
SMYGKQAGFIGTLLSVVRNEGIVALYSGLKATMIRAIPANGALFVAYEYSRKMMMKQLEA
Y

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Ornithine transport across inner mitochondrial membrane, from the cytoplasm to the matrix

# Drug_Target_6_SwissProt_ID:
Q9BXI2

# Drug_Target_6_SwissProt_Name:
ORNT2_HUMAN

# Drug_Target_6_Synonyms:
Solute carrier family 25 member 2

# Drug_Target_6_Theoretical_pI:
9.39

# Drug_Target_6_Transmembrane_Regions:
5-25
68-88
110-130
168-188
210-230
237-257

# Drug_Target_7_Cellular_Location:
Membrane
multi-pass membrane protein (Probable)

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
SLC7A4

# Drug_Target_7_GenBank_ID_Gene:
AJ000730

# Drug_Target_7_GenBank_ID_Protein:
4378940

# Drug_Target_7_GeneCard_ID:
SLC7A4

# Drug_Target_7_Gene_Name:
SLC7A4

# Drug_Target_7_Gene_Sequence:
>1911 bp
ATGGCCCGGGGGCTGCCCACCATTGCTAGCCTGGCACGCTTATGCCAGAAGCTGAACCGC
CTGAAGCCGCTGGAGGACTCCACCATGGAGACGTCACTGCGGCGCTGCCTGTCCACGCTG
GACCTGACTCTTCTGGGCGTGGGTGGCATGGTGGGCTCGGGTCTCTACGTGCTCACAGGT
GCCGTGGCCAAGGAGGTGGCTGGCCCTGCTGTGCTCTTGTCCTTCGGTGTGGCCGCTGTG
GCCTCCCTGCTGGCAGCCCTATGCTATGCAGAATTTGGGGCACGTGTGCCACGCACGGGC
TCTGCCTACCTGTTCACCTACGTATCCATGGGCGAGCTGTGGGCCTTCCTCATCGGCTGG
AATGTTCTCCTCGAATACATCATCGGTGGCGCCGCCGTGGCCCGTGCCTGGAGTGGCTAC
CTGGACTCTATGTTCAGCCACAGCATCCGCAACTTCACTGAAGACCCACGTGGGTTCTTG
GCAGGTGCCCCTCCTGGGCCACTACCCGGACTTCCTGGCTGCTGGCATCATCCTCCCTGG
CCTCTGCCTTTGTCTCCTGTGGAGCCCGCGTGTCCTCCCTGGCTCAATCACACCTTCTCG
GCCATCAGCCTGCTTGTCATTCTCTTCATTGTCATCCTGGGCTTCATCCTGGCCCAGCCT
CACAACTGGAGCGCTGACGAAGGCGGCTTTGCACCCTTCGGCTTCTCCGGCGTCATGGCC
GGCACTGCCTCCTGCTTCTATGCTTTCGTGGGCTTCGACGTCATTGCCGCCTCCAGTGAG
GAGGCCCAGAACCCACGGCGGTCTGTGCCTCTGGCCATCGCCATCTCGCTTGCCATTGCA
GCTGGTGCCTACATCCTTGTCTCCACCGTGCTAACCCTCATGGTGCCCTGGCACAGCCTG
GACCCCGACTCAGCGCTTGCAGATGCCTTCTACCAGCGGGGCTACAGGTGGGCTGGCTTC
ATCGTGGCAGCTGGCTCCATCTGCGCCATGAACACCGTCCTGCTCAGCCTCCTCTTCTCC
CTGCCACGCATTGTCTATGCCATGGCCGCCGATGGGCTCTTCTTCCAGGTGTTTGCCCAT
GTGCACCCCCGGACACAGGTGCCTGTGGCGGGCACCCTGGCGTTCGGGCTCCTCACGGCC
TTCCTGGCACTGCTGCTGGACCTGGAGTCGCTGGTTCAGTTCCTGTCCCTTGGCACACTC
CTGGCCTACACATTCGTGGCCACCAGTATCATTGTGCTGCGCTTCCAGAAGTCTTCCCCG
CCCAGCTCCCCAGGCCCAGCCAGCCCTGGCCCCCTGACCAAGCAGCAGAGCTCCTTCTCA
GACCACCTACAGCTGGTGGGCACTGTACACGCCTCCGTCCCTGAGCCAGGGGAGCTGAAG
CCAGCCCTGAGGCCCTACCTGGGCTTCTTGGATGGGTACAGCCCTGGAGCAGTGGTGACT
TGGGCGCTTGGCGTTATGTTGGCCTCAGCCATCACCATAGGCTGCGTGCTTGTCTTTGGG
AACTCGACCCTGCACCTCCCACACTGGGGTTACATCCTGCTGCTCCTGCTCACCAGTGTC
ATGTTTCTGCTCAGCCTCCTTGTCCTGGGGGCTCACCAGCAACAGTATCGGGAAGACTTA
TTTCAGATCCCCATGGTTCCCCTGATTCCAGCCCTGAGCATCGTCCTCAACATCTGCCTC
ATGCTGAAACTTAGCTATCTGACCTGGGTGCGCTTCTCCATCTGGCTGCTGATGGGACTT
GCAGTGTATTTCGGCTATGGCATCCGGCATAGCAAGGAGAACCAGCGGGAGCTGCCAGGG
CTGAACTCCACACACTACGTGGTATTCCCCAGGGGCAGCCTGGAGGAGACAGTGCAGGCT
ATGCAGCCCCCCAGCCAGGCACCAGCACAGGACCCTGGCCATATGGAGTAG

# Drug_Target_7_General_Function:
Amino acid transport and metabolism

# Drug_Target_7_General_References:
9598310	Sperandeo MP, Borsani G, Incerti B, Zollo M, Rossi E, Zuffardi O, Castaldo P, Taglialatela M, Andria G, Sebastio G: The gene encoding a cationic amino acid transporter (SLC7A4) maps to the region deleted in the velocardiofacial syndrome. Genomics. 1998 Apr 15;49(2):230-6.

# Drug_Target_7_HGNC_ID:
HGNC:11062

# Drug_Target_7_HPRD_ID:
04780

# Drug_Target_7_ID:
58

# Drug_Target_7_Locus:
22q11.21

# Drug_Target_7_Molecular_Weight:
68269

# Drug_Target_7_Name:
Cationic amino acid transporter 4

# Drug_Target_7_Number_of_Residues:
635

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00324	AA_permease

# Drug_Target_7_Protein_Sequence:
>Cationic amino acid transporter 4
MARGLPTIASLARLCQKLNRLKPLEDSTMETSLRRCLSTLDLTLLGVGGMVGSGLYVLTG
AVAKEVAGPAVLLSFGVAAVASLLAALCYAEFGARVPRTGSAYLFTYVSMGELWAFLIGW
NVLLEYIIGGAAVARAWSGYLDSMFSHSIRNFTETHVGSWQVPLLGHYPDFLAAGIILLA
SAFVSCGARVSSWLNHTFSAISLLVILFIVILGFILAQPHNWSADEGGFAPFGFSGVMAG
TASCFYAFVGFDVIAASSEEAQNPRRSVPLAIAISLAIAAGAYILVSTVLTLMVPWHSLD
PDSALADAFYQRGYRWAGFIVAAGSICAMNTVLLSLLFSLPRIVYAMAADGLFFQVFAHV
HPRTQVPVAGTLAFGLLTAFLALLLDLESLVQFLSLGTLLAYTFVATSIIVLRFQKSSPP
SSPGPASPGPLTKQQSSFSDHLQLVGTVHASVPEPGELKPALRPYLGFLDGYSPGAVVTW
ALGVMLASAITIGCVLVFGNSTLHLPHWGYILLLLLTSVMFLLSLLVLGAHQQQYREDLF
QIPMVPLIPALSIVLNICLMLKLSYLTWVRFSIWLLMGLAVYFGYGIRHSKENQRELPGL
NSTHYVVFPRGSLEETVQAMQPPSQAPAQDPGHME

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Involved in the transport of the cationic amino acids (arginine, lysine and ornithine)

# Drug_Target_7_SwissProt_ID:
O43246

# Drug_Target_7_SwissProt_Name:
CTR4_HUMAN

# Drug_Target_7_Synonyms:
CAT-4
CAT4

# Drug_Target_7_Theoretical_pI:
7.08

# Drug_Target_7_Transmembrane_Regions:
42-62
66-86
113-133
197-217
229-249
270-290
318-338
365-385
391-411
478-498
508-528
539-559
567-587

# Drug_Target_8_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
15491978	Rotmann A, Strand D, Martine U, Closs EI: Protein kinase C activation promotes the internalization of the human cationic amino acid transporter hCAT-1. A new regulatory mechanism for hCAT-1 activity. J Biol Chem. 2004 Dec 24;279(52):54185-92. Epub 2004 Oct 15.
16703566	Yeramian A, Martin L, Arpa L, Bertran J, Soler C, McLeod C, Modolell M, Palacin M, Lloberas J, Celada A: Macrophages require distinct arginine catabolism and transport systems for proliferation and for activation. Eur J Immunol. 2006 Jun;36(6):1516-26.
17065601	Cerec V, Piquet-Pellorce C, Aly HA, Touzalin AM, Jegou B, Bauche F: Multiple pathways for cationic amino Acid transport in rat seminiferous tubule cells. Biol Reprod. 2007 Feb;76(2):241-9. Epub 2006 Oct 25.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
SLC7A1

# Drug_Target_8_GenBank_ID_Gene:
X59155

# Drug_Target_8_GenBank_ID_Protein:
36161

# Drug_Target_8_GeneCard_ID:
SLC7A1

# Drug_Target_8_Gene_Name:
SLC7A1

# Drug_Target_8_Gene_Sequence:
>1890 bp
ATGGGGTGCAAAGTCCTGCTCAACATTGGGCAGCAGATGCTGCGGCGGAAGGTGGTGGAC
TGTAGCCGGGAGGAGACGCGGCTGTCTCGCTGCCTGAACACTTTTGATCTGGTGGCCCTC
GGGGTGGGCAGCACACTGGGTGCTGGTGTCTACGTCCTGGCTGGAGCTGTGGCCCGTGAG
AATGCAGGCCCTGCCATTGTCATCTCCTTCCTGATCGCTGCGCTGGCCTCAGTGCTGGCT
GGCCTGTGCTATGGCGAGTTTGGTGCTCGGGTCCCCAAGACGGGCTCAGCTTACCTCTAC
AGCTATGTCACCGTTGGAGAGCTCTGGGCCTTCATCACCGGCTGGAACTTAATCCTCTCC
TACATCATCGGTACTTCAAGCGTAGCGAGGGCCTGGAGCGCCACCTTCGACGAGCTGATA
GGCAGACCCATCGGGGAGTTCTCACGGACACACATGACTCTGAACGCCCCCGGCGTGCTG
GCTGAAAACCCCGACATATTCGCAGTGATCATAATTCTCATCTTGACAGGACTTTTAACT
CTTGGTGTGAAAGAGTCGGCCATGGTCAACAAAATATTCACTTGTATTAACGTCCTGGTC
CTGGGCTTCATAATGGTGTCAGGATTTGTGAAAGGATCGGTTAAAAACTGGCAGCTCACG
GAGGAGGATTTTGGGAACACATCAGGCCGTCTCTGTTTGAACAATGACACAAAAGAAGGG
AAGCCCGGTGTTGGTGGATTCATGCCCTTCGGGTTCTCTGGTGTCCTGTCGGGGGCAGCG
ACTTGCTTCTATGCCTTCGTGGGCTTTGACTGCATCGCCACCACAGGTGAAGAGGTGAAG
AACCCACAGAAGGCCATCCCCGTGGGGATCGTGGCGTCCCTCTTGATCTGCTTCATCGCC
TACTTTGGGGTGTCGGCTGCCCTCACGCTCATGATGCCCTACTTCTGCCTGGACAATAAC
AGCCCCCTGCCCGACGCCTTTAAGCACGTGGGCTGGGAAGGTGCCAAGTACGCAGTGGCC
GTGGGCTCCCTCTGCGCTCTTTCCGCCAGTCTTCTAGGTTCCATGTTTCCCATGCCTCGG
GTTATCTATGCCATGGCTGAGGATGGACTGCTATTTAAATTCTTAGCCAACGTCAATGAT
AGGACCAAAACACCAATAATCGCCACATTAGCCTCGGGTGCCGTTGCTGCTGTGATGGCC
TTCCTCTTTGACCTGAAGGACTTGGTGGACCTCATGTCCATTGGCACTCTCCTGGCTTAC
TCGTTGGTGGCTGCCTGTGTGTTGGTCTTACGGTACCAGCCAGAGCAGCCTAACCTGGTA
TACCAGATGGCCAGTACTTCCGACGAGTTAGATCCAGCAGACCAAAATGAATTGGCAAGC
ACCAATGATTCCCAGCTGGGGTTTTTACCAGAGGCAGAGATGTTCTCTTTGAAAACCATA
CTCTCACCCAAAAACATGGAGCCTTCCAAAATCTCTGGGCTAATTGTGAACATTTCAACC
AGCCTTATAGCTGTTCTCATCATCACCTTCTGCATTGTGACCGTGCTTGGAAGGGAGGCT
CTCACCAAAGGGGCGCTGTGGGCAGTCTTTCTGCTCGCAGGGTCTGCCCTCCTCTGTGCC
GTGGTCACGGGCGTCATCTGGAGGCAGCCCGAGAGCAAGACCAAGCTCTCATTTAAGGTT
CCCTTCCTGCCAGTGCTCCCCATCCTGAGCATCTTCGTGAACGTCTATCTCATGATGCAG
CTGGACCAGGGCACCTGGGTCCGGTTTGCTGTGTGGATGCTGATAGGCTTCATCATCTAC
TTTGGCTATGGCCTGTGGCACAGCGAGGAGGCGTCCCTGGATGCCGACCAAGCAAGGACT
CCTGACGGCAACTTGGACCAGTGCAAGTGA

# Drug_Target_8_General_Function:
Amino acid transport and metabolism

# Drug_Target_8_General_References:
10485994	Kamath SG, Furesz TC, Way BA, Smith CH: Identification of three cationic amino acid transporters in placental trophoblast: cloning, expression, and characterization of hCAT-1. J Membr Biol. 1999 Sep 1;171(1):55-62.
1348489	Albritton LM, Bowcock AM, Eddy RL, Morton CC, Tseng L, Farrer LA, Cavalli-Sforza LL, Shows TB, Cunningham JM: The human cationic amino acid transporter (ATRC1): physical and genetic mapping to 13q12-q14. Genomics. 1992 Mar;12(3):430-4.
1718082	Yoshimoto T, Yoshimoto E, Meruelo D: Molecular cloning and characterization of a novel human gene homologous to the murine ecotropic retroviral receptor. Virology. 1991 Nov;185(1):10-7.

# Drug_Target_8_HGNC_ID:
HGNC:11057

# Drug_Target_8_HPRD_ID:
00091

# Drug_Target_8_ID:
235

# Drug_Target_8_Locus:
13q12-q14

# Drug_Target_8_Molecular_Weight:
67639

# Drug_Target_8_Name:
High-affinity cationic amino acid transporter 1

# Drug_Target_8_Number_of_Residues:
629

# Drug_Target_8_PDB_ID:
Not Available

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00324	AA_permease

# Drug_Target_8_Protein_Sequence:
>High-affinity cationic amino acid transporter 1
MGCKVLLNIGQQMLRRKVVDCSREETRLSRCLNTFDLVALGVGSTLGAGVYVLAGAVARE
NAGPAIVISFLIAALASVLAGLCYGEFGARVPKTGSAYLYSYVTVGELWAFITGWNLILS
YIIGTSSVARAWSATFDELIGRPIGEFSRTHMTLNAPGVLAENPDIFAVIIILILTGLLT
LGVKESAMVNKIFTCINVLVLGFIMVSGFVKGSVKNWQLTEEDFGNTSGRLCLNNDTKEG
KPGVGGFMPFGFSGVLSGAATCFYAFVGFDCIATTGEEVKNPQKAIPVGIVASLLICFIA
YFGVSAALTLMMPYFCLDNNSPLPDAFKHVGWEGAKYAVAVGSLCALSASLLGSMFPMPR
VIYAMAEDGLLFKFLANVNDRTKTPIIATLASGAVAAVMAFLFDLKDLVDLMSIGTLLAY
SLVAACVLVLRYQPEQPNLVYQMASTSDELDPADQNELASTNDSQLGFLPEAEMFSLKTI
LSPKNMEPSKISGLIVNISTSLIAVLIITFCIVTVLGREALTKGALWAVFLLAGSALLCA
VVTGVIWRQPESKTKLSFKVPFLPVLPILSIFVNVYLMMQLDQGTWVRFAVWMLIGFIIY
FGYGLWHSEEASLDADQARTPDGNLDQCK

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
High-affinity, low capacity permease involved in the transport of the cationic amino acids (arginine, lysine and ornithine) in non-hepatic tissues. May also function as an ecotropic retroviral leukemia receptor

# Drug_Target_8_SwissProt_ID:
P30825

# Drug_Target_8_SwissProt_Name:
CTR1_HUMAN

# Drug_Target_8_Synonyms:
CAT-1
CAT1
ERR
Ecotropic retroviral leukemia receptor homolog
Ecotropic retrovirus receptor homolog
System Y+ basic amino acid transporter

# Drug_Target_8_Theoretical_pI:
5.06

# Drug_Target_8_Transmembrane_Regions:
36-57
62-82
103-123
163-183
192-212
247-267
288-307
338-358
385-405
409-429
493-513
527-551
560-580
585-605

# Drug_Target_9_Cellular_Location:
Mitochondrion

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
12874210	Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, Quiceno DG, Ochoa JB, Ochoa AC: L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol. 2003 Aug 1;171(3):1232-9.
14871882	Levillain O, Hus-Citharel A, Garvi S, Peyrol S, Reymond I, Mutin M, Morel F: Ornithine metabolism in male and female rat kidney: mitochondrial expression of ornithine aminotransferase and arginase II. Am J Physiol Renal Physiol. 2004 Apr;286(4):F727-38. Epub 2004 Feb 10.
15539552	Levillain O, Diaz JJ, Blanchard O, Dechaud H: Testosterone down-regulates ornithine aminotransferase gene and up-regulates arginase II and ornithine decarboxylase genes for polyamines synthesis in the murine kidney. Endocrinology. 2005 Feb;146(2):950-9. Epub 2004 Nov 11.
15548540	Bussiere FI, Chaturvedi R, Cheng Y, Gobert AP, Asim M, Blumberg DR, Xu H, Kim PY, Hacker A, Casero RA Jr, Wilson KT: Spermine causes loss of innate immune response to Helicobacter pylori by inhibition of inducible nitric-oxide synthase translation. J Biol Chem. 2005 Jan 28;280(4):2409-12. Epub 2004 Nov 17.
15753084	Nissim I, Luhovyy B, Horyn O, Daikhin Y, Nissim I, Yudkoff M: The role of mitochondrially bound arginase in the regulation of urea synthesis: studies with [U-15N4]arginine, isolated mitochondria, and perfused rat liver. J Biol Chem. 2005 May 6;280(18):17715-24. Epub 2005 Mar 7.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
ARG2

# Drug_Target_9_GenBank_ID_Gene:
D86724

# Drug_Target_9_GenBank_ID_Protein:
1694633

# Drug_Target_9_GeneCard_ID:
ARG2

# Drug_Target_9_Gene_Name:
ARG2

# Drug_Target_9_Gene_Sequence:
>1065 bp
ATGTCCCTAAGGGGCAGCCTCTCGCGTCTCCTCCAGACGCGAGTGCATTCCATCCTGAAG
AAATCCGTCCACTCCGTGGCTGTGATAGGAGCCCCGTTCTCACAAGGGCAGAAAAGAAAA
GGAGTGGAGCATGGTCCCGCTGCCATAAGAGAAGCTGGCTTGATGAAAAGGCTCTCCAGT
TTGGGCTGCCACCTAAAAGACTTTGGAGATTTGAGTTTTACTCCAGTCCCCAAAGATGAT
CTCTACAACAACCTGATAGTGAATCCACGCTCAGTGGGTCTTGCCAACCAGGAACTGGCT
GAGGTGGTTAGCAGAGCTGTGTCAGATGGCTACAGCTGTGTCACACTGGGAGGAGACCAC
AGCCTGGCAATCGGTACCATTAGTGGCCATGCCCGACACTGCCCAGACCTTTGTGTTGTC
TGGGTTGATGCCCATGCTGACATCAACACACCCCTTACCACTTCATCAGGAAATCTCCAT
GGACAGCCAGTTTCATTTCTCCTCAGAGAACTACAGGATAAGGTACCACAACTCCCAGGA
TTTTCCTGGATCAAACCTTGTATCTCTTCTGCAAGTATTGTGTATATTGGTCTGAGAGAC
GTGGACCCTCCTGAACATTTTATTTTAAAGAACTATGATATCCAGTATTTTTCCATGAGA
GATATTGATCGACTTGGTATCCAGAAGGTCATGGAACGAACATTTGATCTGCTGATTGGC
AAGAGACAAAGACCAATCCATTTGAGTTTTGATATTGATGCATTTGACCCTACACTGGCT
CCAGCCACAGGAACTCCTGTTGTCGGGGGACTAACCTATCGAGAAGGCATGTATATTGCT
GAGGAAATACACAATACAGGGTTGCTATCAGCACTGGATCTTGTTGAAGTCAATCCTCAG
TTGGCCACCTCAGAGGAAGAGGCGAAGACTACAGCTAACCTGGCAGTAGATGTGATTGCT
TCAAGCTTTGGTCAGACAAGAGAAGGAGGGCATATTGTCTATGACCAACTTCCTACTCCC
AGTTCACCAGATGAATCAGAAAATCAAGCACGTGTGAGAATTTAG

# Drug_Target_9_General_Function:
Amino acid transport and metabolism

# Drug_Target_9_General_References:
8898077	Gotoh T, Sonoki T, Nagasaki A, Terada K, Takiguchi M, Mori M: Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage-like cell line. FEBS Lett. 1996 Oct 21;395(2-3):119-22.
8954792	Vockley JG, Jenkinson CP, Shukla H, Kern RM, Grody WW, Cederbaum SD: Cloning and characterization of the human type II arginase gene. Genomics. 1996 Dec 1;38(2):118-23.
9256072	Morris SM Jr, Bhamidipati D, Kepka-Lenhart D: Human type II arginase: sequence analysis and tissue-specific expression. Gene. 1997 Jul 9;193(2):157-61.

# Drug_Target_9_HGNC_ID:
HGNC:664

# Drug_Target_9_HPRD_ID:
00143

# Drug_Target_9_ID:
834

# Drug_Target_9_Locus:
14q24.1-q24.3

# Drug_Target_9_Molecular_Weight:
38578

# Drug_Target_9_Name:
Arginase-2, mitochondrial

# Drug_Target_9_Number_of_Residues:
354

# Drug_Target_9_PDB_ID:
1PQ3

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00491	Arginase

# Drug_Target_9_Protein_Sequence:
>Arginase-2, mitochondrial precursor
MSLRGSLSRLLQTRVHSILKKSVHSVAVIGAPFSQGQKRKGVEHGPAAIREAGLMKRLSS
LGCHLKDFGDLSFTPVPKDDLYNNLIVNPRSVGLANQELAEVVSRAVSDGYSCVTLGGDH
SLAIGTISGHARHCPDLCVVWVDAHADINTPLTTSSGNLHGQPVSFLLRELQDKVPQLPG
FSWIKPCISSASIVYIGLRDVDPPEHFILKNYDIQYFSMRDIDRLGIQKVMERTFDLLIG
KRQRPIHLSFDIDAFDPTLAPATGTPVVGGLTYREGMYIAEEIHNTGLLSALDLVEVNPQ
LATSEEEAKTTANLAVDVIASSFGQTREGGHIVYDQLPTPSSPDESENQARVRI

# Drug_Target_9_Reaction:
L-arginine + H2O = L-ornithine + urea

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
May play a role in the regulation of extra-urea cycle arginine metabolism and also in down-regulation of nitric oxide synthesis. Extrahepatic arginase functions to regulate L-arginine bioavailability to NO synthase. Since NO synthase is found in the penile corpus cavernosum smooth muscle, the clitoral corpus cavernosum and the vagina, arginase II plays a role in both male and female sexual arousal. It is therefore a potential target for the treatment of male and female sexual arousal disorders

# Drug_Target_9_SwissProt_ID:
P78540

# Drug_Target_9_SwissProt_Name:
ARGI2_HUMAN

# Drug_Target_9_Synonyms:
Arginase II
Arginase-2, mitochondrial precursor
EC 3.5.3.1
Kidney-type arginase
Non- hepatic arginase

# Drug_Target_9_Theoretical_pI:
6.45

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB00129
